CA1340807C - Nucleic acid amplification process - Google Patents

Nucleic acid amplification process

Info

Publication number
CA1340807C
CA1340807C CA000559709A CA559709A CA1340807C CA 1340807 C CA1340807 C CA 1340807C CA 000559709 A CA000559709 A CA 000559709A CA 559709 A CA559709 A CA 559709A CA 1340807 C CA1340807 C CA 1340807C
Authority
CA
Canada
Prior art keywords
dna
rna
template
polymerase
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000559709A
Other languages
French (fr)
Inventor
Lawrence T. Malek
Cheryl Davey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4137506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1340807(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Priority to CA000559709A priority Critical patent/CA1340807C/en
Priority to US07/211,384 priority patent/US5409818A/en
Priority to AT88113948T priority patent/ATE106948T1/en
Priority to ES88113948T priority patent/ES2053648T3/en
Priority to DE3850093T priority patent/DE3850093T2/en
Priority to EP88113948A priority patent/EP0329822B1/en
Priority to JP1014934A priority patent/JP2650159B2/en
Priority to KR1019890002142A priority patent/KR960015744B1/en
Priority to KR1019910700397A priority patent/KR920702866A/en
Priority to PCT/EP1989/000981 priority patent/WO1991002814A1/en
Priority to US08/386,774 priority patent/US5554517A/en
Priority to US08/606,817 priority patent/US6063603A/en
Priority to JP9057599A priority patent/JPH09327298A/en
Publication of CA1340807C publication Critical patent/CA1340807C/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6865Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

This invention relates to a process for amplifying a specific nucleic acid sequence. The process involves synthesizing single-stranded RNA, single-stranded DNA and double-stranded DNA. The single-stranded RNA is a first template for a first primer, the single-stranded DNA is a second template for a second primer, and the double stranded DNA is a third template for synthesis of a plurality of copies of the first template. A sequence of the first primer or the second primer is complementary to a sequence of the specific nucleic acid and a sequence of the first primer or the second primer is homologous to a sequence of the specific nucleic acid. The amplification process may be used to increase the quantity of the specific nucleic acid sequence to allow detection, or to increase the purity of the specific nucleic acid sequence as a substitute for conventional cloning methodology.

Description

NUCLEIC ACID AMPLIFICATION PROCESS
134~~~?
FIELD OF THE INVENTION
This invention relates to a process for amplifying a specific nucleic acid sequence.
BACKGROUND OF THE INVENTION
The detection of a specific nucleic acid sequence present in a sample by probing the sample with a complementary sequence of nucleic acids is a known diagnostic technique. Nucleic acids are highly specific in binding to complementary nucleic acids and are thus useful to determine whether a specific nucleic acid is present in a sample. One must know the sequence of the specific nucleic acid to be detected and then construct a probe having a complementary nucleic acid sequence to the specific nucleic acid sequence.
In this application, the phrase "specific nucleic acid sequence" means a single stranded or double ,_ ..

1310$x?
stranded nucleic acid; "sample" means a mixture containing nucleic acids; "sufficiently complementary" means that two nucleic acids, a primer and a template, are capable of specific interaction which allows efficient, primer-dependent and template-directed synthesis of DNA, under given conditions of ionic strength and temperature; and "sufficiently homologous"
means that two nucleic acids have similar DNA
sequences and are each capable of interacting with the same DNA primer.
Since nucleic acid probes are highly specific, it is preferable in some situations to probe the nucleic acid sequence itself rather than the protein produced by the nucleic acid sequence. As a particular example, a diagnostic method based solely on protein detection would be unreliable for determining the presence of infectious particles of hepatitis B virus, due to the presence of significant levels of non-infectious antigen particles which lack the DNA
genome. In another example, the various subtypes of human papilloma virus found in either pre-cancerous or benign cervical tumors can be distinguished only by the use of nucleic acid probe hybridization. Also, the microbiology of AIDS makes it certain that an assay based on the presence of AIDS specific nucleic acid sequence would be superior as a diagnostic.
x The greatest difficulty with applying exis~~ ~~
nucleic acid probe technology, and the reason that the utility of the existing probe technology is limited, is the copy number problem. In a virus or cell, for example, there is usually a single copy of a particular gene. This one copy may give rise to many copies of gene product, either RNA or protein. For this reason, diagnostic techniques have often involved probing the protein, since the specific sequence of nucleic acid to be detected may give rise to many thousand copies of protein.
The naturally-occurring high number of ribosomal RNA, up to 100,000 copies per cell, has been used by GenProbe to facilitate diagnosis of certain bacterial pathogens, such as Legionella and Mycoplasma, using nucleic acid probes. However, this strategy cannot be used with non-cellular pathogens, such as viruses.
Copy number is a particular problem with the development of a nucleic acid probe method for the detection of AIDS virus, where the integrated provirus may be present in less than one of ten thousand peripheral blood lymphocytes. Thus, if the particular nucleic acid sequence suspected to be present in a sample could be amplified, the copy number problem could be circumvented and probe assays could be more readily used.
In a normal biological sample, containing only a few cells, and consequently only a few copies of a particular gene, it is necessary to utilize an amplification process in order to overcome the copy number problem.
One method to amplify is to 'grow out' the sample, that is, to arrange conditions so that the living biological material.present in the sample can replicate itself. Replication increases the quantity of nucleic acid sequences to detectable levels. In the food industry, for example, in order to test processed food for the food-poisoning bacteria Salmonella, food samples must be incubated for a number of days to increase the quantity of nucleic acids. In clinical samples, pathogens must also be allowed to increase their number by growing out over some considerable time.
United States Patent No. 4,683,195 issued on July 28. 1987 to Cetus Corporation and United States Patent No. 4,683,202 issued on July 28, 1987 to Cetus Corporation are each directed to a process for amplifying a target nucleic acid sequence contained in a sample. United States Patent No. 4,683,195 relates ".r. ~. .

1340~~7 to a process in which a sample suspected of containing a target nucleic acid sequence is treated with oligonucleotide primers such that a primer extension product is synthesized which in turn serves as a template, resulting in amplification of the target nucleic acid sequence. The primer extension product is separated from the template in the preferred embodiment using heat denaturation. Similarly, United States Patent No. 4,683.202 relates to a process for amplifying a target nucleic acid sequence having two separate complementary strands. The process includes treating the strands with primers to synthesize extension products, separating the primer extension products from the templates, and in turn using the primer extension products as templates.
Both of the above United States patents require either manual or mechanical participation and multi-step operations by the user in the amplification process. The steps involved in these patents require the user to heat the sample, cool the sample, add appropriate enzymes and then repeat the steps. The temperature changes cause the enzymes to lose their activity. Hence, the user is required to repeatedly supplement the amplification mixture with aliquots of appropriate enzymes during the amplification process.
In addition, in United States Patents Nos. 4,683,195 and 4,683,202 each cycle of the amplification process takes place by the synthesis from a first template, of a second template, the second template in turn is used to synthesize the first template. This procedure is repeated, thus, each cycle of the amplification process is based on the synthesis of one product from one substrate.
Notwithstanding the amplification processes disclosed in the prior art, a need exists for improvements to the amplification process. It would be preferable if the amplification process required less participation and fewer manipulations by the user. Further, it would be advantageous if the amplification took place at a relatively constant ambient temperature so that the activity of the enzymes involved in the process would not be affected. It would be more expedient if a template could be used to generate more than one product from one substrate in each cycle of the amplification process.
'~; ~1 1340~~,~
SUN~1ARY OF THE INVENTION
This invention relates to an amplification process which is expedient and requires less participation and fewer manipulations by the user of the process than conventional amplification processes. The amplification takes place at a relatively constant ambient temperature. In addition, each cycle of the process generates a plurality of copies of product from one substrate. The amplification process of this invention may be used to increase the quantity of a specific nucleic acid thus circumventing the copy number problem. Hence, probe assays may be more readily used. The amplification process could also be used to increase the purity of a specific nucleic acid sequence as a substitute for conventional cloning methodology.
One aspect of the invention is a process for amplifying a specific nucleic acid sequence. The process involves the synthesis of single-stranded RNA, single-stranded DNA, and double stranded DNA. The single stranded RNA is a first template for a first primer. The single stranded DNA is a second template for a second ~3~O~u7 primer. The double stranded DNA is a third template for the synthesis of a plurality of copies of the first template. A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
Another aspect of the invention is a process for amplifying a specific nucleic acid sequence. The process involves:
(a) hybridizing a first primer to a first template. The first primer has a DNA
sequence which is sufficiently complementary to a RNA sequence of the first template;
(b) synthesizing a first DNA sequence covalently attached to the first primer and complementary to the RNA sequence of the first template. The first DNA sequence and the first primer comprise a second template;
_ g _ (c) separating the first template from the second template to allow hybridization of a second primer;
(d) hybridizing the second primer to the second template. The second primer has a DNA
sequence which is sufficiently complementary to a DNA sequence of the second template.
(e) synthesizing a second DNA sequence covalently attached to the second primer and complementary to the DNA sequence of the second template and synthesizing a third DNA
sequence covalently attached to the second template and complementary to the DNA
sequence of the second primer. The second and third DNA sequences, the second primer and the second template comprise a third template;
_ g _ 13~U~~~
- to -(f~ synthesizing a plurality of copies of the RNA sequence of the first template from the third template.
A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence.
A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
In a further alternative of the invention, the second primer of DNA has a sequence at its 3' end which is sufficiently complementary to the DNA
sequence of the second template. The second primer has at its 5' end an antisense sequence of a promoter and an antisense sequence of a transcription initiation site for a RNA polymerase.

13~08i37 Another alternative of the invention is a process for amplifying a specific nucleic acid sequence. The process involves combining a first primer, a second primer, ribonuclease H, a RNA-directed DNA polymerase, a DNA-directed DNA polymerase, a RNA polymerase, ribonucleoside triphosphates and deosyribonucleoside triphosphates with a sample. The first primer of DNA
has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and an antisense sequence of a promoter and an antisense sequence of a transcription initiation site which are recognized as substrate by the RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
A further alternative of the invention is a process for amplifying a specific nucleic acid sequence. The process involves adding a first .,.....
primer, a second primer, avian myeloblastosis viral polymerase, E. coli ribonuclease H, bacteriophage T7 RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates to a sample. The first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and an antisense sequence of a promoter and an antisense sequence of a transcription initiation site which are recognized as substrate by T7 RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
BRIEF DESCRIPTION OF THE DRAWINGS
In drawings which illustrate embodiments of the invention, x 134080' Figure 1 is a general illustration of the nucleic acid amplification process;
Figure 2 shows the synthetic oligonucleotide DNA
sequences which are used for testing the amplification process: Figure 2A, the gag test sequence; Figure 2B, the gag2 test sequence;
Figure 3 is an autoradiogram of PAGE analysis of amplification reactions using different primer concentrations;
Figure 4 is an autoradiogram of PAGE analysis of amplification reactions using different template concentrations;
Figure 5 is an autoradiogram of Dot-blot hybridization on amplification reactions;
Figure 6 is an autoradiogram of PAGE analysis of amplification reaction using restriction fragments as template;

1340~~'7 Figure 7 is a general illustration of the indirect nucleic acid amplification process.

~.,~°~~,i~;


1340~~'~
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
This invention relates to a process for amplifying a specific nucleic acid sequence. The amplification involves the alternate synthesis of DNA
and RNA and is generally illustrated in Figure 1. In this process. single-stranded RNA is converted to single-stranded DNA which in turn is converted to a functional template for the synthesis of a plurality of copies of the original single-stranded RNA. A
first primer and a second primer are used in the amplification process. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. In some instances, both the first primer and second primer are sufficiently complementary and sufficiently homologous to a sequence of the specific nucleic acid sequence. for example, if the specific nucleic acid sequence is double stranded DNA.
The RNA is converted to single-stranded DNA by hybridizing an oligonucleotide primer (the first ~~r 13~0~0~
primer) to the RNA (the first template) and synthesizing a complementary strand of DNA from the first primer, (the first DNA sequence) by using a RNA-directed DNA polymerase. The resulting single-stranded DNA (the second template) is separated from the first template by, for example, hydrolysis of the first template and by using a ribonuclease which is specific for RNA-DNA hybrids (for example, ribonuclease H). The second template is converted to a form which is capable of RNA synthesis by hybridizing a synthetic oligonucleotide (the second primer), which contains at its 3' end a sequence which is sufficiently complementary to the 3' end of the second template and toward its 5' end a sequence containing the antisense strand of a promoter and antisense sequence of a transcription initiation site, and by synthesizing a second DNA sequence covalently attached to the 3' end of the second primer using the second template as a template and synthesizing a third DNA sequence covalently attached to the 3' end of the second template using the second primer as a template, using DNA-directed DNA polymerase. The resulting functional derivative of the second template. which is a third template, is used for the synthesis of a plurality of copies of RNA, the first template, by k ,.,~~

13~n~~7 using a RNA polymerase which is specific for the promoter and transcription initiation site defined by the second primer. Each newly synthesized first template can be converted to further copies of the second template and the third template by repeating the cycle. In addition, repetition of the cycle does not require participation or manipulation by the user.
The amplification process commences with the addition of a suitable template nucleic acid to the appropriate enzymes, primers, and cofactors under the appropriate reaction conditions. This template nucleic acid is in a form which is capable of homogenous and continuous amplification and can function as an intermediate in the cycle set forth in Figure 1. The amplification process involves the net consumption of precursors (primers, ribonucleoside triphosphates and deoxyribonucleoside triphosphates) and the net accumulation of products (RNA and DNA).
The processes of RNA and DNA synthesis will proceed asynchronously until sufficient levels of nucleic acids have been synthesized to allow detection. The amplification process may be monitored by, for example, the synthesis of a labeled product from a labeled precursor.

A

It is contemplated that amplification may involve another process either in addition to or in place of the one generally illustrated in Figure 1. Also possible are certain counter-productive enzymatic reactions which occur at permissibly low rates.
Included among the possible non-productive side reactions is the synthesis of RNA and/or DNA in the absence of an added template nucleic acid. Such RNA
and/or DNA products can be discriminated from desired products by determining whether a particular sequence which would be found only between the two priming sites of the specific nucleic acid sequence is present.
The first primer is an oligodeoxyribonucleotide which has at its 3' end a sequence which is sufficiently complementary to the 3' end of the first template. The sequence at the 3' end of the first primer has a particular length and base composition to allow specific and efficient synthesis of the first DNA sequence, under the given conditions of ionic strength and temperature. The first primer may be sufficiently complementary to a region internal to the 3' end of the first template in the fir cycle. In subsequent cycles, the 5' end of the first primer would be complementary to the 3' end of the first d ,.' . .~'C~.v.:~

13400?
template. It is contemplated that the first primer may be composed partially or completely of nucleotides or nucleotide analogs other than the natural deoxyribonucleotides. The 5' end of the first primer may contain sequences which are not complementary to the first template in the first cycle. The non-complementary sequences may be complementary to a nucleic acid which can be immobilized, or to which can be bound a useful non-nucleic acid component, such as a reporter to facilitate detection. Alternatively, the non-complementary sequences may include an antisense sequence of a promoter and an antisense sequence of a transcription initiation site, which could be used for the synthesis of RNA. This RNA
would be complementary to the first template and could be used as an intermediate in another amplification cycle.
The second primer is an oligodeoxyribonucleotide which contains at its 3' end a sequence which is sufficiently complementary to the 3' end of the second template. The second primer has a particular length and base composition to allow specific and efficient synthesis of the second and third DNA sequences, under the given conditions of ionic strength and 1340~i~'l temperature. In addition, the second primer contains the antisense sequence of a functional promoter and the antisense sequence of a transcription initiation site. This sequence, when used as a template for synthesis of the third DNA sequence, contains sufficient information to allow specific and efficient binding of a RNA polymerase and initiation of transcription at the desired site. The promoter sequence may be derived from the antisense strand of a functional promoter. The transcription initiation site may be derived from the 5' terminal sequence of a natural RNA transcript. In the preferred embodiment, the 5'-terminal sequence of the second primer is AATTCTAATACGACTCACTATAGGGAG. This sequence contains the antisense sequence of the promoter and the antisense sequence of the transcription initiation site for T7 RNA polymerase. Alternatively, the transcription initiation site and promoter for another phage RNA polymerase may be used. In addition, sequences which are unrelated to the promoter function may be included at the 5' end of the second primer or between the transcription initiation site and the sequence at the 3' end which hybridizes to the second template. It is contemplated that the second primer may be composed partially or completely of nucleotides or nucleotide analogs other than natural deoxyribonucleotides.

a ,~j l~~d 1~~O~i~'~
All of the enzymes used in this invention should meet certain practical specifications. Each enzyme or enzyme preparation should be free of deleterious deoxyribonuclease ("DNase") activities, such as the 5' or 3' exonuclease activities which are often associated with certain DNA polymerases and single-strand or double-strand specific exonuclease or endonucleases. Each enzyme or enzyme preparation should be free of deleterious ribonuclease ("RNase") activities, with the exception of the preferred addition of a ribonuclease activity which is specific for hybrids of RNA and DNA (for example, ribonuclease H). In addition, each enzyme should be reasonably active under the common reaction conditions which are used for the other enzymatic processes, and non-enzymatic processes, such as hybridizing oligonucleotide primers to the RNA or DNA templates.
The DNA-directed RNA polymerase which is used in this invention may be any enzyme capable of binding to a particular DNA sequence called a promoter and specifically initiating in vitro RNA synthesis at a defined initiation site within close proximity to the promoter. The promoter and the initiation site form part of the second primer. In addition the RNA

;?~-a: .
~k.",a~~~ls.~
isY.r..

1340~i~'~
polymerase should be capable of synthesizing copies of RNA per functional copy of template in a reasonable amount of time. In the preferred embodiment, the bacteriophage T7 RNA polymerase is used. In addition other bacteriophage RNA
polymerase, such as phage T3, phage III, Salmonella phage sp6, or Pseudomonas phage gh-1 may be used. In another embodiment, other prokaryotic or eukaryotic DNA-directed RNA
polymerase may be used. It should be understood that if alternative RNA polymerases are used, then the necessary changes to the promoter and initiation sequences of the second primer should be made according to the template specificity of the particular RNA polymerase.
The RNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a RNA
template. In addition this enzyme may contain activities for DNA-directed DNA polymerase and RNase H. In the preferred embodiment, the avian myeloblastosis viral polymerase ("AMV reverse transcriptase") is used. In addition the RNA-directed DNA polymerase could be from another retrovirus, such as Moloney murine leukemia virus x 13408i~'~
Alternatively, other eukaryotic RNA-directed DNA
polymerases could be used.
The DNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a DNA template. This enzyme should not contain either 5'- or 3'- exonuclease activities, which are associated with many types of DNA
polymerase. In the preferred embodiment, the AMV
reverse transcriptase is used. However, other DNA-directed DNA polymerases which naturally lack the 5'- or 3'- exonuclease activities could be used.
These could include certain eukaryotic DNA
polymerases. such as, DNA polymerase ~ or ~ those DNA polymerases which could be isolated from a mammalian tissue, such as calf thymus. An otherwise unsuitable DNA polymerase could be made useful by removing the undesirable exonuclease activities either by alteration of the DNA polymerase gene followed by expression of the altered polymerase in a suitable host cell, or by chemical modification of the DNA
polymerase protein. Altered versions of DNA
polymerase could be made from the Klenow fragment of E. coli DNA polymerase I or the bacteriophage T7 DNA

polymerase. It should be understood that such alternative DNA-directed DNA polymerase activities are added to supplement the activity contributed by the RNA-directed DNA polymerase, since in the preferred embodiment, both RNA-directed and DNA-directed DNA
polymerase activities are supplied by the same enzyme.
The RNase H which could be used in this invention may be any enzyme capable of hydrolyzing a RNA which is annealed to a complementary DNA. This enzyme should not be capable of hydrolyzing single or double-stranded RNA or any DNA. In the preferred embodiment, the E, coli RNase H is used. In addition, - other RNase H enzymes could be used. such as calf thymus RNase H. Since RNase H is an intrinsic activity of AMV reverse transcriptase, the E. coli RNase H will be supplemented in the preferred embodiment by the RNase H of AMV reverse I
I, transcriptase. Alternatively, any other enzyme i capable of separating the second template from the first template could be used.
The above mentioned enzymes and primers are mixed together in a reaction vessel which contains the necessary buffers and cofactors for both DNA and RNA

synthesis. In addition, the ionic conditions and reaction temperature should be compatible with specific hybridization of the primers to the DNA and RNA templates as is known to those skilled in the art. The reaction mixture should be free of such agents which would interfere with the amplification process, specifically substances which could greatly inhibit the activity of the enzymes, interfere with the hybridizing of primers and templates. or degrade non-productively the nucleic acid intermediates and products.
The description of possible detection schemes may be useful to the application of the amplification process. It should be understood that schemes which may be used for detecting the nucleic acids which are synthesized in the amplification process are not limited to those described herein, and it is contemplated that other methods may be used.
In one embodiment, a labeled precursor may be added to the reaction mixture. Amplification is determined by quantitive or qualitative analysis of labeled products. which can be separated from the labeled precursor by using methods known in the art.

,..",. , A labeled nrE?r~mrcnr may ha a ri hnn"~~1 cne; rlc 1 3 4 ~ ~ !~
triphosphate for detecting RNA synthesis, or a deoxynucleoside triphosphate or an oligonucleotide primer for detecting DNA synthesis. The type of label may be a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten which could bind to an antibody, or possibly a protein or an enzyme. The labeled products may be separated from the labeled precursors on the basis of solubility, charge, or size. In addition, the labeled DNA or RNA may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobi lized .
In another embodiment, the products of the amplification process may be bound to an immobilized support, hybridized to a nucleic acid probe containing a complementary sequence. and separated from the unhybridized nucleic acid probe which remains in solution. The products, DNA or RNA, may be bound directly to a solid support by any stable interaction, such as hydrophobic, electrostatic. or covalent interaction. In addition, the products may contain certain chemical groups, for example, biotin, which may be incorporated into the products during the s .,';~::

~~~~~i~~
amplification process to allow binding to an immobilized protein, for example, avidin or streptavidin. In addition, the products may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized.
The nucleic acid probe would contain a complementary sequence which forms a sufficiently stable interaction with a product of the amplification process to allow binding under the conditions of hybridization and sustained binding under the conditions used for removal of the unhybridized nucleic acid probe. In the preferred embodiment the complementary sequence would be derived from that part of the specific nucleic acid sequence which is between the sequences of the first primer and the second primer. The nucleic acid probe may be a single-stranded DNA or RNA, or a double-stranded DNA or RNA which can be made single-stranded, or an oligonucleotide which can be composed of deoxyribonucleotides and/or ribonucleotides. In addition, the nucleic acid probe may contain a chemical group which could covalently bind to a product DNA or RNA under the appropriate conditions. The nucleic acid probe may be labeled with a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten ~r~
r:, 'r~.r< .

1340b~'~
which could bind to an antibody. In addition, the nucleic acid probe could be conjugated to a protein or enzyme, for example, a phosphatase or a peroxidase.
In addition, the nucleic acid probe may contain sequences which would allow in vitro replication of the probe.
It is contemplated that the products of the amplification process may be analyzed by methods which are typically used for nucleic acids that have been enriched by molecular cloning techniques. In one alternative, the synthesis of a specific DNA sequence may be detected by digestion of the synthesized DNA
with a restriction endonuclease, followed by electrophoretic separation and detection using methods known in the art. In another alternative, the sequence of amplified RNA may be determined by DNA
synthesis using a RNA-directed DNA polymerase, the first primer, and dideoxynucleoside triphosphates (Stoflet gt al., 1988). In another alternative, the sequence of the amplified third template may be determined by RNA synthesis using the DNA-directed RNA
polymerase used in the amplification process, and 3'-deoxyribonucleoside triphosphates (Axelrod &
Kramer, 1985). In another alternative, the amplified 134080' RNA may encode a polypeptide which could be translated, in vitro. The polypeptide product of the in vitro translation could be analyzed by using an antibody.
A sample suspected of containing or known to contain the specific nucleic acid sequence is added to the reaction mixture in the form of a template nucleic acid which is capable of homogeneous and continuous amplification and may be any intermediate in the cycle set forth in Figure 1. In particular, the template nucleic acid may be a single-stranded RNA which contains at its 5' end a sequence which is sufficiently homologous to that which is at the 3' end of the second primer, and contains a sequence at its 3' end which is sufficiently complementary to the first primer. A template nucleic acid of this form would function as a first template in the amplification process. Alternatively, the template nucleic acid may be a single-stranded DNA which contains at its 3' end a sequence which is sufficiently complementary to at least the 3' end of the second primer, and contains a sequence at its 5' end which is sufficiently homologous to that which is at the 3' end of the first primer. A template nucleic acid of this form would function as a 13408~'r second template in the amplification process.
Alternatively, the template nucleic acid may be a double-stranded DNA, one strand of which contains at its 5' end the entire sequence of the second primer and contains a sequence at its 3' end which is sufficiently complementary to the first primer. The double-stranded DNA functions as a third template in the amplification process.
Although the preparation of a template nucleic acid is not part of the amplification process, the description of possible schemes for generating template nucleic acids may be useful to the application of the amplification process. It should be understood that the schemes which may be used for obtaining the template nucleic acid are not limited to the alternatives which are described herein, and it is contemplated that other methods may be used.
In one alternative, a template nucleic acid which could function as a first template could be a naturally occurring RNA or a RNA fragment which could be generated from a larger RNA molecule by using site specific hydrolysis methods known in the art (Shibahara ~ al., 1987).

1340~~'~
In another alternative, a template nucleic acid which could function as a second template could be generated from a double-stranded DNA by digestion with a restriction endonuclease which has a site immediately flanking the sequence which is sufficiently complementary to the 3' end of the second primer. The resulting double-stranded DNA fragments could then be made single-stranded by using chemical or thermal denaturation methods.
In another alternative, a template nucleic acid which could function as a second template could be generated from a single-stranded DNA or RNA to which has been hybridized an oligonucleotide which is capable of blocking DNA synthesis. This blocking oligonucleotide may contain a chemical group, which could covalently bind to the template, under the appropriate conditions. DNA synthesis from this blocked template using the first primer could result in a synthesized DNA with the same 3' end as the second template. If the original template is RNA, then the resulting DNA-RNA hybrid may be used directly as a template nucleic acid. If the original template is DNA, then the resulting copy of the second template could then be separated from the original template by using chemical or thermal denaturation methods.

. 13~0~~'l In another alternative. a template nucleic acid which could function as a third template could be generated from a single-stranded DNA or RNA by DNA
synthesis from the DNA or RNA template using the second primer. The resulting synthesized DNA could then be separated from the original template by using chemical or thermal denaturation methods. In addition, a RNA template could be hydrolyzed by using chemical or enzymatic methods. The resulting single-stranded DNA has the_sequence of the second primer covalently attached to its 5' end and contains a sequence which is sufficiently complementary to the first primer. This single-stranded DNA could be converted to a transcriptionally functional double-stranded DNA by hybridizing the first primer to the single-stranded DNA, and by synthesizing a DNA
sequence which is covalently attached to the first primer and complementary to the single-stranded DNA.
In a further.alternative, a single-stranded DNA
or RNA template could be obtained from a double-stranded DNA, double-stranded RNA or a DNA-RNA
hybrid by using chemical, thermal, or possibly enzymatic methods. Then, by using one of the alternative schemes proposed above, the resulting iA

l~~Day~~
single-stranded DNA or RNA could then be used to generate a template nucleic acid which could function as a first, second or third template. In addition, an alternative scheme involving the first primer and one strand of nucleic acid, and another alternative scheme involving the second primer and the other (complementary) strand of the nucleic acid may be used concurrently to generate template nucleic acids.
MATERIALS AND METHODS
Materials Oligonucleotides were synthesized using an Applied Biosystems 380A DNA synthesizer. Columns, phosphoramidites, and reagents used for oligonucleotide synthesis were obtained from Applied Biosystems, Inc. through Technical Marketing Associates. Oligonucleotides were purified by polyacrylamide gel electrophoresis followed by DEAF
cellulose chromatography. The radioisotope [d~-32P]
UTP (800 Ci/mmol) was from Amersham. Enzymes for digesting and ligating DNA were purchased from New England Biolabs, and used according to the supplier's 13~OS~=~
recommendations. Preparations containing the large fragment of DNA polymerase 1 (Klenow) were also purchased from New England Biolabs. RNasin and T7 RNA
polymerase from Promega Biotec were purchased through Bio/Can Scientific Inc. Reverse transcriptase and RNase H were obtained from Pharmacia. The supplier for proteinase K was Boehringer Mannheim Canada. E.
coli strain HB101 (ATCC 33694) was used for all transformations. The plasmid pUCl9 (Norrander ~ al., 1983) was purchased from Bethesda Research Laboratories.
Isolation of DNA and sequencing E. coli transformants were grown on YT medium (Miller, 1972) containing 50 ug/ml ampicillin.
Plasmid DNA was purified by a rapid boiling method (Holmes and Quigley, 1981). DNA fragments and vectors used for all constructions were separated by electrophoresis on low melting point agarose, and purified from the molten agarose by phenol extraction and ethanol precipitation (Maniatis g~ al., 1982).
Plasmid DNA was sequenced using a modification (Hattori ~ ~. 1985) of the dideoxy method (Sanger g~ al., 1977). Reactions were run using the -20 universal primer (New England Biolabs).

1~~OSi~~
TCA precipitation Aliquots (5u1) of amplification reactions were quenched in 20u1 10 mM EDTA and placed on ice until all time point samples had been collected. The quenched samples were then applied to glass filter discs, and immediately dropped into ice-cold 5%
trichloroacetic acid ("TCA") - 1% sodium pyrophosphate for 10 min with occasional mixing. Two 5 min washes with ice-cold 5% TCA were followed by two additional washes with 95% ethanol and lyophilization to dryness. Radioactivity was determined in a liquid scintillation counter.
Polyacrylamide gel electrophoresis Samples (1 to 6 ul) were mixed with 4-5 ul formamide dye (90% deionized formamide, 10 mM TrisHCl (pH 8.0), 1 mM EDTA, xylene cyanol and bromophenol blue), and applied to a pre-run 12-cm- long 7%
denaturing polyacrylamide gel. Gels were run at 350 volts until the bromophenol blue dye had reached the bottom. In some cases the gels were fixed and dried prior to autoradiography. Fixing involved a 15 min wash in 10% methanol- 7% acetic acid. The profiles of ~~4~~~' the RNA products separated by this procedure were visualized by autoradiography at room temperature.
Example 1: Design and synthesis of oligonucleotides for a gag test system A synthetic DNA sequence (Figure 2A) was designed to include an EcoRI site, a T7 phage promoter, a sequence required for initiation of transcription by T7 RNA polymerase and a 19 by hybridization region (hybridization region 1). The 47 b antisense strand oligonucleotide (T7Hl.GAG) involved in the cloning of these elements also serves as the first primer.
Hybridization region 2 lies 53 by away from hybridization region 1 and is 20 by in length. The primer made to this region (H2.GAG) is a 20 b oligonucleotide duplicate of the sense strand and is not used for cloning. The sequence spanning and including the hybridization regions is a 92 by segment of the gag portion of the HIV-1 genome. This particular gene segment was chosen because the primers were predicted to hybridize efficiently and because the distance between the two hybridization regions was relatively short. In addition, a XbaI site was placed at the end of the sequence for cloning ease. The gag ~3~08~~
test sequence also contains SphI and PstI sites which can aid in the screening of recombinants.
A total of four oligonucleotides were used in the cloning of this fragment. N1.GAG, used in the construction of both the gag test and the gag2 test sequence, completes the antisense strand and is used only in the cloning process. Similarly, T74.PR0 is the sense strand component of the T7 promoter. N2.GAG
however, was used in the construction of both test fragments, and has also been used as an intermediate (second template) in two steps of the amplification cycle. The entire cloned gag test fragment can also represent an intermediate of the amplification cycle (third template). Once cloned into an appropriate vector the gag test DNA could be transcribed by T7 RNA
polymerase to produce a RNA fragment (first template) useful as an amplification intermediate involved in three of the steps. In addition, T7H1.GAG and H2.GAG
serve as primers in the test system.
The gag2 test synthetic DNA fragment (Figure 2B) does not contain the T7 promoter, but the remainder of the sequence is identical to the gag test sequence and therefore, both N1.GAG and N2.GAG were involved in its x ;~
'~ v..

134U8~' construction. The oligonucleotide required to complete the antisense strand is called H1.GAG. Once cloned, the gag2 test fragment can be used as a template for testing amplification, using a DNA
restriction fragment as template nucleic acid.
Example 2: Construction of the gag test plasmids The oligonucleotides T74.PR0 and N1.GAG (2 ug each), were phosphorylated separately in 20 ul reactions containing 70 mM TrisHCl (pH 7.6), 10 mM
MgCl2, 5 mM DTT, 0.5 mM ATP and 5 units T4 polynucleotide kinase, at 37°C for 30 min.
Phosphorylated T74.PR0 and N1.GAG (10 ul of each) were mixed with 1 ug each of unphosphorylated T7Hl.GAG and N2.GAG, and 3 ul 100 mM TrisHCl (pH7.8) - 500 mM NaCl, in a final volume of 29 ul for the gag test assembly.
The gag2 test mixture contained 10 ul phosphorylated N1.GAG, 1 ug each of unphosphorylated H1.GAG and N2.GAG, and 1.8 ul 100 mM TrisHCl (pH 7.8) - 500 mM
NaCl, in a final volume of 18 ul. The oligonucleotide mixtures were hybridized separately by placing them at 90°C for 10 min followed by slow cooling to room temperature for 10 to 16 h 60 ul reactions containing 50 mM TrisHCl (pH 7.8), 10 mM MgCl2, 20 mM DTT, 1mM

13~0~~'I
ATP and 50 ug/ml BSA were used to ligate the hybridized oligonucleotides together. 400 units T4 DNA ligase was added to the gag test reaction and it was incubated at 15°C for 2h while the gag2 test reaction was incubated for 14 to 16 h with 200 units T4 DNA ligase.
The isolated and purified synthetic DNA segments were mixed with plasmid pUCl9 which had been linearized by digestion at restriction enzyme sites within the polylinker region. T4 DNA ligase was used to ligate the gag test sequence into the EcoRI- XbaI
fragment of pUCl9, while the gag2 test sequence was ligated to the SmaI-XbaI fragment. Plasmid DNA from transformants obtained after these reactions were used to transform E. coli were screened by restriction analysis , and the final plasmids (pGAG.TEST and pGAG2.TEST) were determined to be correct by sequence analysis.
Example 3: Effect of primer concentration on RNA
amplification The reaction mixtures (25 ul) which were used to amplify RNA transcribed from the gag test ,..Y I

1340~0'r oligonucleotides contained 50 nM TrisHC1 (pH
8.45), 6 mM MgCl2 40 mM KC1, 10 mM
dithiothreitol, 0.5 mM NTP (ATP, CTP, GTP, UTP), 1 mM dNTP (dATP, dCTP, dGTP, dTTP), 20 units RNasin, 10 units T7 RNA polymerase, 10 units reverse transcriptase, 0.4 units RNase H, and 10 uCi [ a -32P] UTP. Two of the reactions contained 0.5 ng (0.015 pmoles) N2.GAG while the other two reactions contained no template. The primers T7Hl.GAG and H2.GAG were each added at final concentrations of 3.4 uM or 0.34 uM to reactions containing either N2.GAG or no template. The reactions were incubated at 42°C
for 2h. Total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min. intervals. The effect of the primer concentration on template-dependent RNA
synthesis is shown in Table 1. Aliquots of each reaction, containing equal amounts of synthesized RNA, were analyzed by PAGE and autoradiography (Figure 3, lanes 1-4 numbered the same as the reactions).
Table 1: RNA amplification after 2 h.
Concentration of Template RNA

Reaction each primier (ng) Synthesized (uM) (ug) 1 3.4 0.5 2.8 2 3.4 - 2.1 3 0.34 0.5 1.8 4 0.34 - 0,-7 13408i~'7 It was found that while reaction 1 resulted in the greatest incorporation of isotope, the no template control, reaction 2, was also high (73% of reaction 1) and produced a very similar electrophoretic profile.
It would therefore appear that in the presence of high primer concentrations, a RNA transcript of identical size to that expected in amplification is produced in the absence of any template. Results using samples with a 10- fold decrease in primer concentration were dramatically different. The amount of RNA produced in reaction 3 was 2.6 times that of reaction 4, but while virtually all of the transcript was found in a single band of the expected size in reaction 3, no fragments greater than 60 to 70 b were found in reaction 4.
Primer concentration therefore plays a significant role in the accuracy and efficiency of RNA
amplification.
A control RNA transcript used to represent the size of fragment expected to be generated by the amplification system (lane 0 of Figure 3) was prepared by transcription from the test plasmid. pGAG.TEST was linearized by digestion with XbaI, proteinase K
treated (Maniatis g~ al., 1982), phenol extracted and ethanol precipitated. T7 RNA polymerase was then used 134~8~'~
according to the supplier's recommendations to transcribe 0.5 ug of the resulting fragment in a 25 ul reaction mixture containing 10 uCi [ a' -32P] UTP.
example 4: Effect of template concentration on RNA
amplification The standard 50 ul reaction mixture used to amplify RNA transcribed from the gag test oligonucleotides contained 0.34 uM T7H1.GAG, 0.34 uM
H2.GAG, 50 mM TrisHCl (pH 8.45), 6 mM MgCl2, 40 mM
KC1, 10 mM DTT, 0.5 mM NTP, 1 mM dNTP, 40 units RNasin, 20 units T7 RNA polymerase, 20 units reverse transcriptase, 0.8 units RNase H and 10 - 20 uCi [ ~-32P] UTP. The reactions contained amounts of template (N2.GAG) varying from 1 ng to 1 fg. One reaction contained no template. The reactions were incubated at 42°C for 3h, during which total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min intervals. As indicated in Table 2, total RNA synthesis was higher than the no template control for all template concentrations tested. Although the total synthesis of RNA generally decreased with decreasing template concentration, this decrease in synthesis was not Z~40~0'l quantitative. Thus, the degree of amplification of RNA per starting template generally increased with decreasing template concentration. Amplification of 8 x 108 fold was achieved by synthesis of 0.8 ug RNA
from 1 fg of N2.GAG template. One fg of the 102 b N2.GAG oligonucleotide represents approximately 2 a 104 molecules.
Table 2: RNA amplification from N2.GAG after 3h.
RNA

Synthesized Fold Reaction Template (ug) amplifi cation 1 1 ng 3.5 3.5 x 103 2 100 pg 4.4 4.4 x 104 3 10 pg 4.1 4.1 x 105 4 1 pg 3.0 3.0 x 106 5 100 fg 2.7 2.7 x 107 6 10 fg 1.9 1.9 x 108 7 1 fg 0.78 7.8 x 108 8 - 0Ø46 -The RNA which was synthesized after a reaction time of 3h was analyzed by PAGE, for each template concentration (Figure 4 lanes 1-8, numbered the same as the reactions). A major band representing a RNA of about 100 b was present in all reactions except the ones containing 1 fg template and no template. The reaction containing 1 fg template did not have much of this 100 b product at 3 h but the overall RNA

.1~~C~~i~'l synthesis was higher than and qualitatively different from the no template reaction.
Example 5: Hybridization analysis of RNA products.
Amplification reactions containing amounts of N2.GAG template varying from 1 pg to 0.1 fg were performed following the teaching of example 4, except the radiolabeled UTP was omitted. The reactions were incubated at 42°C for 3 h. Aliquots were removed from each reaction at 30 min intervals and applied to a nylon membrane (Amersham). The nucleic acids that were contained in these reaction aliquots were fixed by exposure to ultraviolet light. The membrane was prehybridized at 50°C for 1 h in prehybridization buffer consisting of a final concentration of 50% v/v formamide, 5 X SSC and 5 X Denhardt's solution (Maniatis ~ ~. 1982; Southern g~ al., 1975) at a volume equivalent to 5 mls of solution per 100 cm2 and hybridized with a radiolabeled probe with a specific activity of 106 cpm/ml of hybridization solution. Hybridization was performed at 50°C for 16 h in 50% formamide, 5 X SSC and 5 X Denhardt's solution (Maniatis g~ ~. 1982; Southern g~ al., 1975). The radiolabeled probe was the synthetic ~3408J7 oligonucleotide 5' GATCTGGGATAGAGTACATCCA 3' which had been labeled at the 5' end using T4 polynucleotide kinase and ( Y - 3zP) ATP. After the membrane was washed at 50°C in a series of 2, 3 min. washes consisting of 2 X SSC, 0.1$ v/v SDS and 0.2 X SCC, 0.1~ v/v SDS (Southern et al., 1975; Maniatis et al., 1982; Szostak et al., 1979).
Figure 5 shows the results of the hybridization analysis performed on the amplification reactions, containing various amounts of N2.GAG template, which were sampled at different times of incubation.
Each column of Figure 5 represents a different time point (l, 30 min; 2, 60 min; 3, 90 min; 4, 120 min; 5, 150 min; 6, 180 min) and each row represents a different amount of added N2.GAG template (1, lpg; 2, 100 fg; 3, 10 fg; 4, 1 fg; 5, 0.1 fg; 6, no template). Amplification of nucleic acids which hybridized to the labeled probe were observed for rows 1-3 (1 pg - 10 fg), however the hybridization to specific nucleic acids in rows 4 - 5 (1 fg, 0.1 fg) was not higher than row 6 (no template). The apparent non-specific binding of labeled probe in row 6 seems to be related to DNA or RNA synthesis since the hybridization signal increases with increasing time.

.-13~U8~~
Example 6: Use of DNA restriction fragment as template.
The plasmid pGAG2.TEST was digested with MspI and proteinase K, purified by phenol extraction and ethanol precipitation, and denatured by boiling for 5 min. Amplification reactions were performed and analyzed following the teaching of Example 4, except the MspI digested pGAG2.TEST was used as a template instead of the N2.GAG oligonucleotide. The amounts of plasmid added to each reaction varied from 55 ng to 5.5 pg, and no template. To simulate additional DNA
which would be present in an actual sample, alternate reactions contained 1 ng of calf thymus DNA which had been similarly digested, purified and denatured.
After a 3 h incubation at 42°C, the synthesis of RNA
was determined by TCA precipitation and PAGE
analysis. As indicated in Table 3, total RNA
synthesis was higher than the no template controls for all template concentrations tested. The degree of amplification was calculated based on RNA synthesis from the actual template which was 1.8% of the total plasmid DNA.
The total RNA synthesis (degree of amplification) from a particular initial level template concentration ~r~, m:,, 1340~0'~
was consistently lower for the restriction.fragment (Table 3) as compared to that for the synthetic oligonucleotide template (Table 2). This could be due to competition with the complementary strand of the restriction fragment template under the conditions used.
Table 3: RNA amplification from MspI-digested pGAG2.TEST
RNA Fold Reaction Template* Synth esized** amplific ation**

1 55.0 ng [ 1 ng] 3.65 3.7 x 103 2 (4.05) (4.1 x 103) 3 5.5 ng [100 pg] 3.54 3.5 x 104 4 (3.16) (3.2 x 104) 5 550.0 pg [ 10 pg] 2.29 2.3 x 105 6 (2.79) (2.8 x 105) 7 55.0 pg [ 1 pg] 2.62 2.6 x 106 8 (0.67) (0.7 x 106) 9 5.5 pg [100 fg] 1.37 1.4 x 107 10 (2.26) (2.3 x 107) 11 - 1.25 -12 (0.08) 2 0 * Numbersis brackets indicate valent amountsof GAG.
equi N2.

** Numbers in parentheses indicateRNA synthesisin ce of presen 1 ug MspI-di gested calf thymus DNA.

,. ~ 1340~i~'~

The RNA which was synthesized after a reaction time of 3h was analyzed by PAGE (Figure 6, lanes 1-6, 11 and 12, numbered the same as the reactions). The major band representing a RNA of about 100 b was present in reactions (lanes) 1-6 but absent in the no template reactions (lanes 11 and 12). The RNA in lane 0 was a standard, which was prepared following the teaching of Example 3. There was no apparent qualitative difference in the synthesized RNA either with (lanes 2, 4 and 6) or without (lanes 1, 3, and 5) the additional of 1 ~g of MspI-digested calf thymus DNA.
Although preferred embodiments of the invention have been described in detail, it will be understood by those skilled in the art that variations may be made thereto without departing from either the spirit of the invention or the scope of the appended claims.

~.. 1340~i~r~
References 1. Abbott, M.A., Poiesz, B.J., Byrne, B.C., Kwok, S., Sninsky, J.J., and Ehrlich, G.D. (1988), J. Inf.
Diseases ~$, 1158 2. Axelrod, V.D. and Kramer, F.R. (1985) Biochemistry 24, 5716-5723.
3. Biebricher, C.K. (1987) Cold Spring Harbor Symp.
Quant. Biol. 52, 299-306 4. Bugawan, T.L., Saiki, R.K., Levenson, C.H., Watson, R.M. and Erlich, H.A. (1988) Biotechnology _6, 943-947 5. Chu, B.C.F., Kramer, F.R. and Orgel, L.E. (1986) Nucleic Acids Res. 14, 5591-5603 6. Denhardt, D.T. (1966) Biochem. Biophy. Res. Commun.
_2~ 641-646 7. Harbarth, P. and Vosberg, H.P. (1988) DNA 7, 297-306 8. Hattori, M., Hidaka, S., and Sakaki, Y. (1985) Nucleic Acids Res. 13, 7813-7827.
9. Holmes, D.S. and Quigley, M. (1981) Anal. Biochem.
114, 193-197.
10. Kawaski, E.S., Clark, S.S., Coyne, M.Y., Smith, S.D., Champlin, R., Witte, O.N. and McCormick, F.P. (1988) Proc. Nat'1. Acad. Sc. U.S.A. ~1_, 5698-5702 11. Klenow, H. and I. Henningsen (1970) Proc. Nat'1. Acad.
Sc. U.S.A. 65, 168 12. Lizardi, R.M., Guerra, C.E., Lomeli, H., Tussie-Luna, I, and Kramer, F.R. (1988) Biotechnology f, 1197-1202 13. Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
14. Miller, J.H. (1972) Experiments in Molecular Genetics, P. 433. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

134080'1 15. Mullis, K.B. and Faloona, F.A. (1987) Methods Enzymology 155, 335-350 16. Murakawa, G.J., Zaia, J.A., Spallone, P.A., Stephens, D.A., Kaplan, B.E., Wallace, R.B. and Rossi, J.J.
(1988) DNA ~ 287-295 17. Norrander, J., Kempe, T., and Messing, J. (1983) Gene 26, 101-106 18. Ou, C.Y., Kwok, S., Mitchell, S.W., Mack, D.H., Sninsky, J.J., Krebs, J.W., Feorino, P., Warfield, D.
and Schochetman, G. (1988) Science 239, 295-297 19. Saiki, R.K., Bugawan, T.L., Horn, G.T., Mullis, K.B.
and Erlich, H.A. (1966) Nature 324, 163-166 20. Saiki, R.K., Galfaud, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. and Erlich, H.A.
(1988) Science 239, 487-491 21. Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N. (1985) Science 23 1350-1354 22. Sanger, F., Nicklen, S., and Coulson, A.R. (1977) Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467.
23. Shibahara, S., Mukai, S., Nishihara, T., Inoue, H., Ohtsuka, E., and Morisawa, H. (1987) Nucleic Acid Res. l~, 4403-4415.
24. Shibata, D.K., Arnheim, N. and Martin, W.J. (1988) J.
Exp. Med. 167, 225-230 25. Southern, E. (1975) J. Mol. Biol. ~$, 503.
26. Stoflet, E.S., Koebarl, D.D., Sarkar, G., and Sommer, S.S. (1988) Science 239, 491-494 27. Stoflet, E.S., Koebarl, D.D., Sarkar, 6, and Sommer, S.S. (1988) Science 239, 491-494.
28. Szostak, J.W., Stiles, J.I., Tye, B.-K., Chiu, P., Shemran, F., and Wu, R. (1979) Methods in Enzymology 68. 419.
29. Szostak, J.W. Stiles, J.I., Tye, B.-K., Chiu, P., Shemran, F., and Wu, R. (1979) Methods in Enzymology 68, 491.

Claims (44)

1. A process for the amplification of a specific nucleic acid sequence, at a relatively constant temperature and without serial addition of reagents, comprising the steps of:
(A) providing a single reaction medium containing reagents comprising (i) a first oligonucleotide primer;
(ii) a second oligonucleotide primer comprising an antisense sequence of a promoter recognized by an RNA polymerase;
(iii) a DNA-directed RNA polymerase that recognizes said promoter;
(iv) an RNA-directed DNA polymerase;
(v) a DNA-directed DNA polymerase;
(vi) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA, and (vii) ribonucleoside and deoxyribonucleoside triphosphates;
then (B) providing in said reaction medium RNA comprising an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence, under conditions such that a cycle ensues wherein (i) said first oligonucleotide primer hybridizes to said RNA first template;
(ii) said RNA-directed DNA polymerase uses said RNA first template to synthesize a DNA
second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate:
(iii) said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid intermediate;
(iv) said second oligonucleotide primer hybridizes to said DNA second template;
(v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as a template to synthesize a functional promoter recognized by said RNA polymerase by extension of said DNA second template;
(vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template;
and thereafter (C) maintaining said conditions for a time sufficient to achieve a desired amplification of said specific nucleic acid sequence.
2. A process according to claim 1, wherein said RNA
first template comprises said specific nucleic acid sequence and wherein step (B) comprises providing single-stranded RNA to said reaction medium such that (i) said first oligonucleotide primer hybridizes to said single-stranded RNA;
(ii) said RNA-directed DNA polymerase uses said single-stranded RNA as a template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid;
(iii) said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid;
(iv) said second oligonucleotide primer hybridizes to said DNA second template;
(v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize a functional promoter recognized by said DNA-directed RNA polymerase by extension of said DNA second template;
and (vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA
second template, thereby providing copies of said RNA first template.
3. A process according to claim 2, wherein step (B) comprises adding to said reaction medium single-stranded RNA.
4. A process according to claim 1, wherein said RNA
first template comprises a sequence complementary to said specific nucleic acid sequence and wherein step (B) comprises adding single-stranded RNA to said reaction medium such that (i) said second oligonucleotide primer hybridizes to said single-stranded RNA;
(ii) said RNA-directed DNA polymerase uses said RNA
as a template to synthesize a complementary DNA
by extension of said second oligonucleotide primer and thereby forms an RNA-DNA hybrid;
(iii) said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid;
(iv) said first oligonucleotide primer hybridizes to said complementary DNA;
(v) said DNA-directed DNA polymerase uses said complementary DNA as template to synthesize said DNA second template and a functional promoter recognized by said RNA polymerase by extension of said first oligonucleotide primer;

and (vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA
second template thereby providing copies of said RNA first template.
5. A process according to claim 4, wherein step (B) comprises adding to said reaction medium said single-stranded RNA.
6. A process according to claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises an antisense sequence of a promoter recognized by said RNA
polymerase, such that (i) said first oligonucleotide primer hybridizes to said single-stranded DNA;
(ii) said DNA-directed DNA polymerase uses said single-stranded DNA as template to synthesize said DNA second template and a functional promoter recognized by said DNA-directed RNA
polymerase by extension of said first oligonucleotide primer;
and (iii) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA
second template, thereby providing copies of said RNA first template.
7. A process according to claim 6, wherein step (B) comprises adding to said reaction medium an RNA-DNA
hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.
8. A process according to claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises said DNA second template, such that (i) said second oligonucleotide primer hybridizes to said single-stranded DNA;
(ii) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize a functional promoter recognized by said DNA-directed RNA polymerase by extension of said DNA second template;
and (iii) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA
second template, thereby providing copies of said RNA first template.
9. A process according to claim 8, wherein step (B) comprises adding to said reaction medium an RNA-DNA
hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.
10. A process according to claim 2, wherein step (B) comprises adding to said reaction medium a DNA
comprising a functional promoter recognized by said RNA polymerase, such that said DNA-directed RNA
polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.
11. A process according to claim 4, wherein step (B) comprises adding to said reaction medium a DNA
comprising a functional promoter recognized by said RNA polymerase, such that said DNA-directed RNA
polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.
12. A process according to claim 1, wherein said second oligonucleotide primer further comprises an antisense sequence of a transcription initiation site for said DNA-directed RNA polymerase, said antisense sequence of said transcription initiation site being operatively linked to said antisense sequence of said promoter.
13. A process according to claim 12, wherein said DNA-directed RNA polymerase is bacteriophage T7 RNA
polymerase and wherein said antisense sequence of a transcription initiation site and said antisense sequence of said promoter together comprise the nucleotide sequence:
AATTCTAATACGACTCACTATAGGGAG.
14. A process according to claim 1, wherein step (B) further comprises adding a sample to said reaction medium under conditions such that, if said sample thereby provides RNA comprising an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence, said cycle ensues, and wherein said process further comprises, after step (C), a step (D) of monitoring said reaction medium for consumption of any of said reagents (i), (ii) and (vii) or for accumulation of any product of said cycle.
15. A process according to claim 14, wherein step (D) comprises detecting a nucleic acid product of said cycle.
16. A process according to claim 15, wherein step (D) comprises detecting said nucleic acid product using a nucleic acid probe.
17. A process according to claim 15, wherein step (D) comprises detecting said nucleic acid product using restriction endonucleases and electrophoretic separation.
18. A process according to claim 15, wherein step (D) comprises monitoring the accumulation of said RNA
first template.
19. A process according to claim 15, wherein step (D) comprises monitoring the accumulation of said DNA
second template.
20. A process according to claim 15, wherein step (D) comprises monitoring DNA containing a functional promoter recognized by said RNA polymerase.
21. A process according to claim 15, wherein step (D) comprises monitoring the accumulation of said RNA-DNA
hybrid intermediate.
22. A process according to claim 14, wherein step (D) further comprises comparing consumption of any reagent of said reagents (i), (ii) and (vii) of step (A) or accumulation of any product of said cycle with a value representing consumption of said reagent or accumulation of said product in said reaction medium in the absence of said specific nucleic acid sequence and said sequence complementary thereto.
23. A process according to claim 1, wherein said ribonuclease comprises Escherichia coli ribonuclease H.
24. A process according to claim 1, wherein said ribonuclease comprises calf thymus ribonuclease H.
25. A process according to claim 1, wherein said first oligonucleotide primer or said second oligonucleotide primer is bound reversibly to an immobilized support.
26. A process according to claim 1, wherein said DNA-directed RNA polymerase is a bacteriophage RNA
polymerase.
27. A process according to claim 26, wherein said DNA-directed RNA polymerase is bacteriophage T7 RNA
polymerase.
28. A process according to claim 26, wherein said DNA-directed RNA polymerase is bacteriophage T3 polymerase.
29. A process according to claim 26, wherein said DNA-directed RNA polymerase is bacteriophage ~II
polymerase.
30. A process according to claim 26, wherein said DNA-directed RNA polymerase is Salmonella bacteriophage sp6 polymerase.
31. A process according to claim 26, wherein said DNA-directed RNA polymerase is Pseudomonas bacteriophage gh-1 polymerase.
32. A process according to claim 1, wherein said RNA-directed DNA polymerase is a retroviral reverse transcriptase.
33. A process according to claim 32, wherein the said retroviral reverse transcriptase is avian myeloblastosis virus reverse transcriptase.
34. A process according to claim 32, wherein said retrovirus reverse transcriptase is a Moloney murine leukemia virus reverse transcriptase.
35. A process according to claim 1, wherein said DNA-directed RNA polymerase lacks exonuclease activity.
36. A process according to claim 1, wherein all DNA
polymerases in said reaction medium lack DNA
exonuclease and endonuclease activity.
37. A process according to claim 1, wherein said DNA-directed DNA polymerase is avian myeloblastosis virus polymerase.
38. A process according to claim 1, wherein said DNA-directed DNA polymerase is DNA polymerase ~ or .beta..
39. A process according to claim 1, wherein said DNA-directed DNA polymerase is calf thymus DNA
polymerase.
40. A process according to claim 1, wherein step (C) comprises maintaining said conditions for a period of time between 30 minutes and 3 hours.
41. A process according to claim 1, further comprising the steps of ligating a DNA product of said cycle into a cloning vector and then cloning said DNA
product.
42. A process according to claim 41, further comprising the step of expressing a product encoded by said DNA
product of said cycle in an expression system.
43. A kit for amplifying nucleic acid molecules, comprising an assemblage of:
(A) a first oligonucleotide primer having a DNA
sequence sufficiently complementary to an RNA
sequence of a first template to be amplified;

(B) a second oligonucleotide primer comprising an antisense sequence of a promoter recognized as a substrate for an RNA polymerase and having a DNA
sequence sufficiently complementary to a DNA
sequence of a second template;
(C) a ribonuclease that hydrolyzes RNA of an RNA/DNA
hybrid without attacking single-stranded or double-stranded RNA or DNA;
(D) an RNA-directed DNA polymerase;
(E) DNA-directed DNA polymerase;
(F) a DNA-directed RNA polymerase;
(G) ribonucleoside triphosphates; and (H) deoxyribonucleoside triphosphates;
where the DNA sequence of the second template is complementary to the RNA sequence of the first template.
44. A kit for amplifying a specific nucleic acid molecules comprising:
(A) a first oligonucleotide primer having a DNA
sequence sufficiently complementary to an RNA
sequence of a first template to be amplified;
(B) a second oligonucleotide primer comprising an antisense sequence of a promoter recognized as a substrate for an RNA polymerase and having a DNA
sequence sufficiently complementary to a DNA
sequence of a second template;

(C) Escherichia coli ribonuclease H;
(D) avian myeloblastosis virus reverse transcriptase;
(E) bacteriophage T7 RNA polymerase;
(F) ribonucleoside triphosphates; and (G) deoxyribonucleoside triphosphates;
where the DNA sequence of the second template is complementary to the RNA sequence of the first template.
CA000559709A 1988-02-24 1988-02-24 Nucleic acid amplification process Expired - Lifetime CA1340807C (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA000559709A CA1340807C (en) 1988-02-24 1988-02-24 Nucleic acid amplification process
US07/211,384 US5409818A (en) 1988-02-24 1988-06-24 Nucleic acid amplification process
AT88113948T ATE106948T1 (en) 1988-02-24 1988-08-26 METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS.
ES88113948T ES2053648T3 (en) 1988-02-24 1988-08-26 PROCESS OF EXPANSION OF A NUCLEIC ACID.
DE3850093T DE3850093T2 (en) 1988-02-24 1988-08-26 Methods for amplifying nucleic acids.
EP88113948A EP0329822B1 (en) 1988-02-24 1988-08-26 Nucleic acid amplification process
JP1014934A JP2650159B2 (en) 1988-02-24 1989-01-24 Nucleic acid amplification method
KR1019890002142A KR960015744B1 (en) 1988-02-24 1989-02-23 Nucleic acid amplication process
KR1019910700397A KR920702866A (en) 1988-02-24 1989-08-19 Nucleic Acid Amplification Method
PCT/EP1989/000981 WO1991002814A1 (en) 1988-02-24 1989-08-19 Nucleic acid amplification process
US08/386,774 US5554517A (en) 1988-02-24 1995-02-10 Nucleic acid amplification process
US08/606,817 US6063603A (en) 1988-02-24 1996-02-26 Nucleic acid amplification process
JP9057599A JPH09327298A (en) 1988-02-24 1997-03-12 Amplification of nucleic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000559709A CA1340807C (en) 1988-02-24 1988-02-24 Nucleic acid amplification process

Publications (1)

Publication Number Publication Date
CA1340807C true CA1340807C (en) 1999-11-02

Family

ID=4137506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000559709A Expired - Lifetime CA1340807C (en) 1988-02-24 1988-02-24 Nucleic acid amplification process

Country Status (8)

Country Link
US (1) US5409818A (en)
EP (1) EP0329822B1 (en)
KR (2) KR960015744B1 (en)
AT (1) ATE106948T1 (en)
CA (1) CA1340807C (en)
DE (1) DE3850093T2 (en)
ES (1) ES2053648T3 (en)
WO (1) WO1991002814A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044184B2 (en) 2004-04-26 2011-10-25 Wako Pure Chemical Industries, Ltd. Probe and primer for tubercle bacillus detection, and method of detecting human tubercle bacillus therewith

Families Citing this family (712)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
JP2650159B2 (en) * 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー Nucleic acid amplification method
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
DE68928769T2 (en) * 1988-12-09 1999-04-01 Amrad Corp Ltd AMPLIFIED DNS ASSAY
JP3152927B2 (en) * 1988-12-16 2001-04-03 アクゾ・ノベル・ナムローゼ・フェンノートシャップ Self-sustaining, sequence replication system
IE66597B1 (en) * 1989-05-10 1996-01-24 Akzo Nv Method for the synthesis of ribonucleic acid (RNA)
US6589734B1 (en) * 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
US5766849A (en) * 1989-07-11 1998-06-16 Gen-Probe Incorporated Methods of amplifying nucleic acids using promoter-containing primer sequence
DK0408295T3 (en) * 1989-07-11 1996-09-16 Gen Probe Inc Methods for amplifying nucleic acid sequences
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
WO1991004340A1 (en) * 1989-09-20 1991-04-04 Cambridge Biotech Corporation In vitro, isothermal nucleic acid amplification
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
IE65771B1 (en) * 1990-01-25 1995-11-15 Zeneca Ltd Amplification of nucleotide sequences using vectorette units
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
WO1991013994A1 (en) * 1990-03-13 1991-09-19 Commonwealth Scientific And Industrial Research Organisation Gene expression
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
US5194370A (en) * 1990-05-16 1993-03-16 Life Technologies, Inc. Promoter ligation activated transcription amplification of nucleic acid sequences
JP3392863B2 (en) * 1990-07-24 2003-03-31 エフ.ホフマン ― ラ ロシュ アーゲー Reduction of non-specific amplification in in vitro nucleic acid amplification using modified nucleobases
DE69106998T2 (en) 1990-10-05 1995-05-24 Akzo Nobel Nv Antibodies against hepatitis virus non-A, non-B immunochemically reactive peptides.
NZ240079A (en) * 1990-10-09 1993-07-27 Boehringer Mannheim Gmbh Method for the detection of a nucleic acid or part thereof
RU2017821C1 (en) * 1990-10-10 1994-08-15 Анатолий Михайлович Онищенко Method of dna amplification and a device for its realization
IE913930A1 (en) * 1990-11-13 1992-06-17 Siska Diagnostics Nucleic acid amplification by two-enzyme, self-sustained¹sequence replication
US5518900A (en) * 1993-01-15 1996-05-21 Molecular Tool, Inc. Method for generating single-stranded DNA molecules
WO1992018521A1 (en) * 1991-04-10 1992-10-29 Life Technologies, Inc. Method for amplifying and altering an rna sequence
WO1992020820A1 (en) * 1991-05-15 1992-11-26 Vanderbilt University Method to determine metastatic potential of tumor cells
EP0517361A1 (en) * 1991-05-30 1992-12-09 Amoco Corporation A method for detecting and identifying pathogenic organisms using target sequences as detectors
US5169766A (en) * 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5137814A (en) * 1991-06-14 1992-08-11 Life Technologies, Inc. Use of exo-sample nucleotides in gene cloning
US5229283A (en) * 1991-06-14 1993-07-20 Life Technologies, Inc. Use of exo-sample nucleotides in gene cloning
ATE257860T1 (en) * 1991-08-02 2004-01-15 Biomerieux Bv QUANTIFICATION OF NUCLEIC ACIDS
DE4129653A1 (en) * 1991-09-06 1993-03-11 Boehringer Mannheim Gmbh PROCESS FOR DETECTION OF SIMILAR NUCLEIC ACIDS
DK0534640T3 (en) * 1991-09-23 1997-03-17 Pfizer
DE4132133A1 (en) * 1991-09-26 1993-04-01 Boehringer Mannheim Gmbh METHOD FOR THE SPECIFIC PRODUCTION OF RIBONUCLEIC ACIDS
DE4213029A1 (en) * 1991-09-26 1993-04-01 Boehringer Mannheim Gmbh METHOD FOR THE SPECIFIC REPRODUCTION OF NUCLEIN'S SEQUENCES
US5981179A (en) * 1991-11-14 1999-11-09 Digene Diagnostics, Inc. Continuous amplification reaction
WO1993014217A1 (en) * 1992-01-10 1993-07-22 Life Technologies, Inc. Use of predetermined nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules
CA2128891A1 (en) * 1992-01-29 1993-08-05 Cylia Keller Polynucleotide immobilized support
US6100099A (en) 1994-09-06 2000-08-08 Abbott Laboratories Test strip having a diagonal array of capture spots
IT1262937B (en) * 1992-04-13 1996-07-22 Enichem Spa IN VITRO GENE SELECTION BY RNA CARRIERS
WO1993022461A1 (en) * 1992-05-06 1993-11-11 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
US5807669A (en) * 1992-05-11 1998-09-15 Schuepbach; Joerg Process for the detection of reverse transcriptase
US5843640A (en) * 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
US5580971A (en) * 1992-07-28 1996-12-03 Hitachi Chemical Company, Ltd. Fungal detection system based on rRNA probes
JPH07509361A (en) * 1992-07-28 1995-10-19 日立化成工業株式会社 gene detection system
US5614389A (en) * 1992-08-04 1997-03-25 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
WO1994003624A1 (en) * 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US6261808B1 (en) 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
US5733733A (en) * 1992-08-04 1998-03-31 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
ZA936016B (en) * 1992-08-24 1994-03-10 Akzo Nv Method for nucleic acid amplification
ZA936015B (en) * 1992-08-24 1994-03-10 Akzo Nv Elimination of false negatives in nuleic acid detection.
DE4236708A1 (en) * 1992-10-30 1994-05-05 Bayer Ag Specific gene probes and methods for the diagnosis of Candida albicans
DE4302459A1 (en) * 1993-01-29 1994-08-04 Bayer Ag Nucleotides containing sulfocoumarin and their use in detection methods for nucleic acids
ES2056028B1 (en) * 1993-02-18 1995-04-01 Inia PROCEDURE FOR THE SELECTION OF OLIGONUCLEOTIDES FOR THE SPECIFIC AMPLIFICATION OF HIGHLY VARIABLE GENOMES.
DE4344742A1 (en) * 1993-06-09 1994-12-15 Boehringer Mannheim Gmbh Method for the immobilization of nucleic acids
WO1995003430A1 (en) * 1993-07-23 1995-02-02 Gen-Probe Incorporated Methods for enhancing nucleic acid amplification
FR2708288B1 (en) * 1993-07-26 1995-09-01 Bio Merieux Method for amplification of nucleic acids by transcription using displacement, reagents and necessary for the implementation of this method.
GB2284209A (en) * 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
WO1995015399A1 (en) 1993-12-01 1995-06-08 Toyo Boseki Kabushiki Kaisha Method of amplifying and detecting target nucleic acid sequence by using thermostable enzymes
CA2185239C (en) * 1994-03-16 2002-12-17 Nanibhushan Dattagupta Isothermal strand displacement nucleic acid amplification
AU2215995A (en) * 1994-04-07 1995-10-30 Akzo Nobel N.V. Freeze-dried compositions comprising rna
US5863724A (en) * 1994-04-13 1999-01-26 Baylor College Of Medicine Methods of screening for persistent hyperinsulinemic hypoglycemia of infancy
DE4421901A1 (en) 1994-06-23 1996-01-04 Bayer Ag A rapid DNA test for the detection of quinolone-resistant Staphylococcus aureus pathogens in clinical specimens
AU711115B2 (en) * 1994-07-15 1999-10-07 Akzo Nobel N.V. Use of RNA polymerase to improve nucleic acid amplification process
AU707317B2 (en) * 1994-08-18 1999-07-08 Akzo Nobel N.V. Primers and probes for the amplification and detection of CMV nucleic acid
US6010847A (en) 1994-08-18 2000-01-04 Akzo Nobel N.V. Oligonucleotides that can be used in the amplification and detection of CMV nucleic acid
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
FR2724934B1 (en) * 1994-09-26 1997-01-24 Bio Merieux CHIMERIC OLIGONUCLEOTIDE AND ITS USE IN OBTAINING NUCLEIC ACID TRANSCRIPTS
EP0710724A2 (en) 1994-10-06 1996-05-08 Akzo Nobel N.V. Toxoplasma gondii antigens
FR2726277B1 (en) 1994-10-28 1996-12-27 Bio Merieux OLIGONUCLEOTIDE FOR USE AS PRIMER IN AN AMPLIFICATION METHOD BASED ON REPLICATION WITH MOVEMENT OF STRAND
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5849879A (en) * 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5654141A (en) * 1994-11-18 1997-08-05 Thomas Jefferson University Amplification based detection of bacterial infection
US6001610A (en) * 1994-11-23 1999-12-14 Roche Diagnostics, Gmbh Method for the particularly sensitive detection of nucleic acids
DE4441626A1 (en) * 1994-11-23 1996-05-30 Boehringer Mannheim Gmbh Method for the particularly sensitive detection of nucleic acids
US5665545A (en) * 1994-11-28 1997-09-09 Akzo Nobel N.V. Terminal repeat amplification method
CA2206451C (en) * 1994-12-09 2002-11-26 Wakunaga Seiyaku Kabushiki Kaisha Method for suppressing nonspecific hybridization in primer extension method
CA2139070C (en) * 1994-12-23 2010-03-30 Burton W. Blais Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction
US5925518A (en) * 1995-05-19 1999-07-20 Akzo Nobel N.V. Nucleic acid primers for amplification of a mycobacteria RNA template
US5856096A (en) * 1995-09-20 1999-01-05 Ctrc Research Foundation Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5747255A (en) * 1995-09-29 1998-05-05 Lynx Therapeutics, Inc. Polynucleotide detection by isothermal amplification using cleavable oligonucleotides
JP3974941B2 (en) 1995-11-21 2007-09-12 イェール ユニバーシティ Amplification and detection of single molecule segments
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6048688A (en) * 1996-11-12 2000-04-11 Kimberly-Clark Corporation Method for detection of Pseudomonas aeruginosa using polymerase chain reaction
US20080160524A1 (en) * 1996-01-24 2008-07-03 Third Wave Technologies, Inc. Methods and Compositions for Detecting Target Sequences
US7195871B2 (en) * 1996-01-24 2007-03-27 Third Wave Technologies, Inc Methods and compositions for detecting target sequences
EP0914462A4 (en) * 1996-03-18 2002-05-22 Molecular Biology Resources Target nucleic acid sequence amplification
PT938320E (en) 1996-03-26 2010-09-22 Michael S Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
JPH09289900A (en) * 1996-04-26 1997-11-11 Toyobo Co Ltd Amplifier of nucleic acid of cytomegalovirus (cmv) utilizing nucleic sequence (beta 2.7) and reagent kit for detection
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5770368A (en) * 1996-05-09 1998-06-23 Metropolitan Water District Of Southern California Cryptosporidium detection method
US6436638B1 (en) 1996-05-09 2002-08-20 Metropolitan Water District Of Southern California Cryptosporidium detection method
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5866336A (en) * 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
JPH1028585A (en) * 1996-07-16 1998-02-03 Toyobo Co Ltd Amplification of nucleic acid using heat-stable ribonuclease h
CA2262019C (en) 1996-08-02 2011-11-15 Bio Merieux Target nucleic acid sequence amplification method
JP2000516468A (en) * 1996-08-14 2000-12-12 ライフ テクノロジーズ,インコーポレイテッド Stable compositions for nucleic acid amplification and sequencing
US6132954A (en) * 1996-08-20 2000-10-17 Baylor College Of Medicine Methods of screening for agents that delay a cell cycle and compositions comprising era and an analogue of wild-type era
EP1007730A4 (en) * 1996-08-30 2004-04-28 Invitrogen Corp METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US6096273A (en) * 1996-11-05 2000-08-01 Clinical Micro Sensors Electrodes linked via conductive oligomers to nucleic acids
US7381525B1 (en) * 1997-03-07 2008-06-03 Clinical Micro Sensors, Inc. AC/DC voltage apparatus for detection of nucleic acids
US6379929B1 (en) 1996-11-20 2002-04-30 The Regents Of The University Of Michigan Chip-based isothermal amplification devices and methods
US20040142327A1 (en) * 1996-11-22 2004-07-22 Jhy-Jhu Lin Methods for identifying and isolating DNA polymorphisms or genetic markers
CA2274587A1 (en) 1996-12-10 1998-06-18 Genetrace Systems Inc. Releasable nonvolatile mass-label molecules
US6025133A (en) * 1996-12-30 2000-02-15 Gen-Probe Incorporated Promoter-sequestered oligonucleoside and method of use
US5861295A (en) 1997-01-02 1999-01-19 Life Technologies, Inc. Nucleic acid-free thermostable enzymes and methods of production thereof
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6306588B1 (en) 1997-02-07 2001-10-23 Invitrogen Corporation Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof
US6713300B1 (en) 1997-02-27 2004-03-30 University Of Utah Research Foundation Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
EP1005481B1 (en) 1997-04-22 2009-10-14 Life Technologies Corporation Methods for the production of aslv reverse transcriptases composed of multiple subunits
ID25877A (en) 1997-08-08 2000-11-09 Akzo Nobel Nv NUCLEIC ACID SEQUENCE THAT CAN BE USED AS A PRIMARY AND STRONG IN THE APPLICATION AND DETECTION OF THE WHOLE HIV-1 SUBTYPE
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
WO1999013113A1 (en) * 1997-09-12 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Non-competitive co-amplification methods
US6225097B1 (en) 1997-09-17 2001-05-01 Toyota Jidosha Kabushiki Kaisha Decaprenyl diphosphate synthetase gene
AU741141B2 (en) 1997-11-04 2001-11-22 Roche Diagnostics Gmbh Specific and sensitive method for detecting nucleic acids
ZA989950B (en) * 1997-11-17 1999-05-04 Akzo Nobel Nv Transcription based amplification of double stranded DNA targets
ATE544857T1 (en) 1997-12-18 2012-02-15 Monsanto Technology Llc INSECT-RESISTANT TRANSGENIC PLANTS AND METHOD FOR IMPROVING THE ACTIVITY OF DELTA-ENDOTOXINS AGAINST INSECTS
US5968732A (en) * 1997-12-31 1999-10-19 Akzo Nobel, N.V. Isothermal transcription based assay for the detection and genotyping of dengue virus
US6093542A (en) * 1998-01-09 2000-07-25 Akzo Nobel N.V. Isothermal transcription based amplification assay for the detection and quantitation of macrophage derived chemokine RNA
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
CA2319170A1 (en) 1998-01-27 1999-07-29 Clinical Micro Sensors, Inc. Amplification of nucleic acids with electronic detection
US6686150B1 (en) 1998-01-27 2004-02-03 Clinical Micro Sensors, Inc. Amplification of nucleic acids with electronic detection
USH1825H (en) * 1998-01-30 1999-12-07 Akzo Nobel N.V. Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA
US6365346B1 (en) * 1998-02-18 2002-04-02 Dade Behring Inc. Quantitative determination of nucleic acid amplification products
US7026112B1 (en) * 1998-03-04 2006-04-11 Akzo Nobel N.V. Oligonucleotides for the amplification and detection of Epstein Barr Virus (EBV) nucleic acid
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
JP4196236B2 (en) 1998-03-17 2008-12-17 東洋紡績株式会社 Nucleic acid amplification reagent and sequence-specific nucleic acid amplification method
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
JP4438110B2 (en) * 1998-07-01 2010-03-24 東ソー株式会社 Quantification method of target nucleic acid
WO2000004193A1 (en) 1998-07-20 2000-01-27 Yale University Method for detecting nucleic acids using target-mediated ligation of bipartite primers
EP1114184A2 (en) * 1998-09-15 2001-07-11 Yale University Molecular cloning using rolling circle amplification
US7029861B1 (en) 1998-09-15 2006-04-18 Board Of Regents, The University Of Texas System LPS-response gene compositions and methods
CA2342837A1 (en) 1998-09-15 2000-03-23 Yale University Artificial long terminal repeat vectors
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6743906B1 (en) 1998-10-02 2004-06-01 Board Of Regents, The University Of Texas PPP2R1B is a tumor suppressor
US6153411A (en) 1998-10-30 2000-11-28 American Water Works Company, Inc. Methods and kits for detection of Cryptosporidium parvum using immunomagnetic separation and amplification
EP1829856A3 (en) * 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
MXPA01005267A (en) * 1998-11-27 2002-04-24 Synaptics Uk Ltd Position sensor.
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US6187566B1 (en) 1999-03-09 2001-02-13 Applied Gene Technologies, Inc. Method of labeling a nucleic acid amplicon with simultaneous contamination prevention
WO2000056916A2 (en) * 1999-03-18 2000-09-28 Exiqon A/S Detection of mutations in genes by specific lna primers
US6630333B1 (en) * 1999-03-23 2003-10-07 Invitrogen Corporation Substantially pure reverse transriptases and methods of production thereof
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6582906B1 (en) * 1999-04-05 2003-06-24 Affymetrix, Inc. Proportional amplification of nucleic acids
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
DE19916929A1 (en) 1999-04-15 2000-10-19 Bayer Ag New oligonucleotide primers, useful for amplifying human telomerase RNA for diagnosis, prognosis and monitoring of cancer
ATE413467T1 (en) 1999-04-20 2008-11-15 Illumina Inc DETECTION OF NUCLEIC ACID REACTIONS ON BEAD ARRAYS
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US20030207295A1 (en) * 1999-04-20 2003-11-06 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
WO2000066780A2 (en) 1999-04-30 2000-11-09 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
AU5008900A (en) * 1999-05-12 2000-11-21 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US8080380B2 (en) * 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
AU776129B2 (en) * 1999-05-21 2004-08-26 Invitrogen Corporation Compositions and methods for labeling of nucleic acid molecules
DE60045350D1 (en) 1999-06-01 2011-01-20 Baylor College Medicine COMPOSITIONS AND METHODS FOR THE THERAPEUTIC APPLICATION OF A SEQUENCE ASSOCIATED WITH THE GEN ATONAL
US7537886B1 (en) 1999-06-22 2009-05-26 Life Technologies Corporation Primers and methods for the detection and discrimination of nucleic acids
US6830902B1 (en) * 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US6495320B1 (en) 1999-07-21 2002-12-17 Affymetrix, Inc. Even length proportional amplification of nucleic acids
ATE417127T1 (en) 1999-07-26 2008-12-15 Clinical Micro Sensors Inc NUKELIC ACID SEQUENCE DETERMINATION USING ELECTRONIC DETECTION
US6864050B2 (en) * 1999-07-30 2005-03-08 Affymetrix, Inc. Single-phase amplification of nucleic acids
US6379930B1 (en) 1999-07-30 2002-04-30 Applied Gene Technologies, Inc. Stabilization of nucleic acid amplification cocktails
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US6692918B2 (en) 1999-09-13 2004-02-17 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
US6958225B2 (en) 1999-10-27 2005-10-25 Affymetrix, Inc. Complexity management of genomic DNA
NZ539430A (en) 1999-12-10 2006-09-29 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
US6582938B1 (en) 2001-05-11 2003-06-24 Affymetrix, Inc. Amplification of nucleic acids
US6794138B1 (en) * 1999-12-16 2004-09-21 Affymetrix, Inc. Methods of small sample amplification
US20050214825A1 (en) * 2000-02-07 2005-09-29 John Stuelpnagel Multiplex sample analysis on universal arrays
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US8076063B2 (en) * 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
US7955794B2 (en) * 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001064959A1 (en) * 2000-03-02 2001-09-07 Akzo Nobel N.V. Detection of hepatitis b virus rna
ATE294855T1 (en) * 2000-03-07 2005-05-15 Biomerieux Bv RNA POLYMERASE MUTANTS WITH INCREASED THERMOSTABILITY
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
EP2295551B1 (en) 2000-05-26 2016-04-06 Life Technologies Corporation Thermostable reverse transcriptases and uses thereof
US7078208B2 (en) 2000-05-26 2006-07-18 Invitrogen Corporation Thermostable reverse transcriptases and uses thereof
EP1158055A1 (en) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Method for diagnosing cancers
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US7846733B2 (en) * 2000-06-26 2010-12-07 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
JP2004513617A (en) * 2000-06-26 2004-05-13 ニューゲン テクノロジーズ, インコーポレイテッド Methods and compositions for transcription-based nucleic acid amplification
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
AU2001271722B2 (en) 2000-06-30 2006-04-13 Qiagen, Gmbh Signal amplification with lollipop probes
JP4813746B2 (en) 2000-07-10 2011-11-09 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Chromosome 3p21.3 gene is a tumor suppressor
JP2002142765A (en) * 2000-07-14 2002-05-21 Tosoh Corp New method for analyzing genom
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE60040874D1 (en) 2000-09-01 2009-01-02 Gen Probe Inc AMPLIFYING HIV-1 SEQUENCES FOR THE DETECTION OF VEN
US6858412B2 (en) * 2000-10-24 2005-02-22 The Board Of Trustees Of The Leland Stanford Junior University Direct multiplex characterization of genomic DNA
KR20040034582A (en) * 2000-12-04 2004-04-28 프리마겐 홀딩 비.브이. Testing endosymbiont cellular organelles and compounds identifiable therewith
EP2105496B1 (en) 2000-12-08 2013-02-20 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
CA2430329A1 (en) * 2000-12-13 2002-06-20 Nugen Technologies, Inc. Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
US6794141B2 (en) * 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
KR20030064420A (en) * 2000-12-26 2003-07-31 다카라 바이오 가부시키가이샤 Method of detecting pathogenic microorganism
US6893847B2 (en) * 2001-01-17 2005-05-17 Tosoh Corporation Oligonucleotide for detecting Salmonella and method of detecting Salmonella
WO2002062993A1 (en) * 2001-02-06 2002-08-15 Takara Bio Inc. Amplified nucleic acids and immobilized products thereof
KR100809949B1 (en) * 2001-02-15 2008-03-06 다카라 바이오 가부시키가이샤 Method of detecting nucleotide polymorphism
US6620586B2 (en) * 2001-02-20 2003-09-16 Applied Gene Technologies, Inc. Methods and compositions for analyzing nucleic acids
WO2002068683A2 (en) * 2001-02-27 2002-09-06 Virco Bvba Circular probe amplification (cpa) using energy-transfer primers
ATE361996T1 (en) * 2001-03-09 2007-06-15 Nugen Technologies Inc METHODS AND COMPOSITIONS FOR DUPLICATION OF RNA SEQUENCES
US6573051B2 (en) 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
CA2439074A1 (en) * 2001-03-09 2002-09-19 Nugen Technologies, Inc. Methods and compositions for amplification of rna sequences
US20030092157A1 (en) * 2001-03-16 2003-05-15 Hayden Michael R. Compositions, screening systems and methods for modulating HDL cholesterol and triglyceride levels
US6596489B2 (en) 2001-03-30 2003-07-22 Applied Gene Technologies Methods and compositions for analyzing nucleotide sequence mismatches using RNase H
US7838270B2 (en) * 2001-05-22 2010-11-23 The University Of Chicago Target-dependent transcription using deletion mutants of N4 RNA polymerase
WO2002095002A2 (en) 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
US8137911B2 (en) * 2001-05-22 2012-03-20 Cellscript, Inc. Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
US20050003356A1 (en) * 2001-05-25 2005-01-06 Hayden Michael R. Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
JPWO2002101042A1 (en) * 2001-06-12 2005-04-07 タカラバイオ株式会社 Method for stabilizing and storing reagent for nucleic acid amplification or detection reaction
MXPA03012075A (en) * 2001-06-22 2005-07-01 Marshfield Clinic Methods and oligonucleotides for the detection of $i(salmonella) sp., $i(e. coli) o157:h7, and $i(listeria monocytogenes ).
ATE414711T1 (en) * 2001-06-28 2008-12-15 Mountain View Pharmaceuticals POLYMER-STABILIZED PROTEINASES
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US20040161741A1 (en) * 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US9777312B2 (en) * 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
EP2246438B1 (en) 2001-07-12 2019-11-27 Illumina, Inc. Multiplex nucleic acid reactions
DK1421215T3 (en) * 2001-07-25 2011-06-27 Oncomedx Inc Methods for evaluating pathological conditions using extracellular RNA
US6872529B2 (en) * 2001-07-25 2005-03-29 Affymetrix, Inc. Complexity management of genomic DNA
US7297778B2 (en) * 2001-07-25 2007-11-20 Affymetrix, Inc. Complexity management of genomic DNA
AU2002312543A1 (en) 2001-08-01 2003-02-17 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
TWI335938B (en) * 2001-08-15 2011-01-11 Rna replication and amplification
KR20040028991A (en) * 2001-08-20 2004-04-03 다카라 바이오 가부시키가이샤 Nucleic acid amplification methods
US7432084B2 (en) * 2001-08-31 2008-10-07 Rosetta Inpharmatics Llc Methods for preparing nucleic acid samples
JP2005532780A (en) 2001-09-19 2005-11-04 インタージェネティックス インコーポレイテッド Genetic analysis for stratification of cancer risk
EP1908851A3 (en) 2001-09-19 2008-06-25 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20030165859A1 (en) 2001-10-23 2003-09-04 Invitrogen Corporation Primers and methods for the detection and discrimination of nucleic acids
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
AU2002358110A1 (en) 2001-12-10 2003-07-09 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
ES2405790T3 (en) 2001-12-17 2013-06-03 Corixa Corporation Compositions and methods for therapy and diagnosis of inflammatory bowel disease
CN1281324C (en) * 2001-12-19 2006-10-25 阿菲梅特里克斯公司 Manufacturing process for array plate assembly
WO2003064679A2 (en) * 2002-01-30 2003-08-07 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7354742B2 (en) 2002-02-22 2008-04-08 Ortho-Mcneil Pharmaceutical, Inc. Method for generating amplified RNA
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
CA2477670A1 (en) * 2002-03-15 2003-09-25 Arcturus Bioscience, Inc. Improved nucleic acid amplification
EP1573056A4 (en) * 2002-05-17 2007-11-28 Nugen Technologies Inc Methods for fragmentation, labeling and immobilization of nucleic acids
US20030219754A1 (en) * 2002-05-23 2003-11-27 Oleksy Jerome E. Fluorescence polarization detection of nucleic acids
US20030219755A1 (en) * 2002-05-24 2003-11-27 Nanibhushan Dattagupta Compositions and methods for performing hybridization assays using target enhanced signal amplification (TESA)
JP4570565B2 (en) 2002-07-15 2010-10-27 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Screening of combinatorial protein libraries by periplasmic expression
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
US20040011650A1 (en) * 2002-07-22 2004-01-22 Frederic Zenhausern Method and apparatus for manipulating polarizable analytes via dielectrophoresis
AU2003254298A1 (en) 2002-08-02 2004-02-23 Stratatech Corporation Species specific dna detection
AU2003257109A1 (en) * 2002-08-05 2004-02-23 Invitrogen Corporation Compositions and methods for molecular biology
US20060099224A1 (en) 2002-08-12 2006-05-11 David Kirn Methods and compositions concerning poxviruses and cancer
AU2003270310A1 (en) * 2002-09-05 2004-03-29 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
EP1554377B1 (en) 2002-09-13 2012-11-07 Life Technologies Corporation Thermostable reverse transcriptases and uses thereof
AU2002951411A0 (en) 2002-09-16 2002-09-26 The University Of Sydney Genotype screen
EP1546170A4 (en) 2002-09-20 2007-08-29 Univ Yale Riboswitches, methods for their use, and compositions for use with riboswitches
US20040259105A1 (en) * 2002-10-03 2004-12-23 Jian-Bing Fan Multiplex nucleic acid analysis using archived or fixed samples
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20040096829A1 (en) * 2002-11-14 2004-05-20 Allaire Normand E. Absolute quantitation of nucleic acids by RT-PCR
AU2003297557B2 (en) * 2002-11-21 2009-02-26 Cellscript, Inc. Methods for using primers that encode one strand of a double-stranded promoter
CN1230531C (en) * 2002-12-09 2005-12-07 清华大学 Method and kit for separating cell particle from sample
CN1223680C (en) 2002-12-10 2005-10-19 清华大学 Method and kit for amplifying nucleic acid of target cell or virus
EP1573009B1 (en) 2002-12-18 2011-09-21 Third Wave Technologies, Inc. Detection of small nucleic acids
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US7955795B2 (en) * 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7297780B2 (en) 2003-01-06 2007-11-20 Third Wave Technologies, Inc. Reactive functional groups for preparation of modified nucleic acid
PL220536B1 (en) 2003-01-06 2015-11-30 Corixa Corp Certain amionicalcylivglucosaminiumphosphate compounds and their application
US6852494B2 (en) * 2003-01-10 2005-02-08 Linden Technologies, Inc. Nucleic acid amplification
WO2004083806A2 (en) 2003-01-22 2004-09-30 University Of South Florida Autonomous genosensor apparatus and methods for use
WO2005003375A2 (en) 2003-01-29 2005-01-13 454 Corporation Methods of amplifying and sequencing nucleic acids
US6943768B2 (en) 2003-02-21 2005-09-13 Xtellus Inc. Thermal control system for liquid crystal cell
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
WO2004085670A2 (en) * 2003-03-24 2004-10-07 Perkinelmer Las, Inc. Polarization detection
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
WO2004092412A2 (en) 2003-03-31 2004-10-28 Roche Diagnostics Gmbh Compositions and methods for detecting certain flaviviruses, including members of the japanese encephalitis virus serogroup
US20040265870A1 (en) * 2003-04-09 2004-12-30 Invitrogen Corporation Methods of synthesizing and labeling nucleic acid molecules
CA2521084A1 (en) * 2003-04-14 2004-10-28 Nugen Technologies, Inc. Global amplification using a randomly primed composite primer
WO2005000098A2 (en) 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
US20050059054A1 (en) 2003-07-25 2005-03-17 Richard Conrad Methods and compositions for preparing RNA from a fixed sample
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
EP1660631B1 (en) * 2003-08-01 2013-04-24 Life Technologies Corporation Compositions and methods for purifying short rna molecules
CA2538222A1 (en) 2003-09-12 2005-03-24 Stephen Bryant Liggett Methods for risk assessment, survival prediction and treatment of heart failure and other conditions based on adrenergic receptor polymorphisms
DK1709198T3 (en) 2003-11-26 2013-09-02 Advandx Inc Peptide Nucleic Acid Probes for the Analysis of Certain Staphylococcus Species
JP2007512838A (en) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション Nucleic acid molecules containing recombination sites and methods of use thereof
EP1711591A4 (en) 2003-12-29 2010-04-28 Nugen Technologies Inc Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
EP1718743B1 (en) * 2004-02-04 2009-08-26 QIAGEN North American Holdings, Inc. Anti-freeze protein enhanced nucleic acid amplification
CA2497324A1 (en) 2004-02-17 2005-08-17 Affymetrix, Inc. Methods for fragmenting and labelling dna
WO2005112544A2 (en) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
EP1574583A1 (en) * 2004-03-10 2005-09-14 Roche Diagnostics GmbH Methods for isolation of bacteria from biological samples
US7462451B2 (en) * 2004-04-26 2008-12-09 Third Wave Technologies, Inc. Compositions for modifying nucleic acids
WO2005118810A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
US7307802B2 (en) 2004-06-07 2007-12-11 Fluidigm Corporation Optical lens system and method for microfluidic devices
US7776530B2 (en) * 2004-06-29 2010-08-17 Wallac Oy Integrated nucleic acid analysis
WO2006000647A1 (en) * 2004-06-29 2006-01-05 Wallac Oy Integrated non-homogeneous nucleic acid amplification and detection
EP1767655A4 (en) 2004-07-13 2007-08-01 Takeda Pharmaceutical Method of controlling cell functions
US7713697B2 (en) * 2004-08-27 2010-05-11 Gen-Probe Incorporated Methods and kits for amplifying DNA
EP2071031B1 (en) * 2004-08-27 2013-10-09 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
ES2345993T3 (en) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING.
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
US20060068430A1 (en) * 2004-09-20 2006-03-30 Sigma-Aldrich Co. Purification of biomolecules from contaminating intact nucleic acids
EP1645640B1 (en) 2004-10-05 2013-08-21 Affymetrix, Inc. Method for detecting chromosomal translocations
EP1652580A1 (en) 2004-10-29 2006-05-03 Affymetrix, Inc. High throughput microarray, package assembly and methods of manufacturing arrays
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
US20060223084A1 (en) * 2004-12-06 2006-10-05 Bioveris Corporation Methods and compositions for detecting Bacillus anthracis
KR20070093992A (en) * 2004-12-11 2007-09-19 사이토제닉, 인크. Cell free biosynthesis of high-quality nucleic acid and uses thereof
US7579153B2 (en) 2005-01-25 2009-08-25 Population Genetics Technologies, Ltd. Isothermal DNA amplification
US9505846B2 (en) 2005-01-28 2016-11-29 Life Technologies Corporation Multi-component inhibitors of nucleic acid polymerases
EP2529619B1 (en) 2005-02-17 2015-09-23 Biogen MA Inc. Treating neurological disorders
EP1874955A4 (en) 2005-02-28 2009-05-06 Bioquest Inc Methods for performing direct enzymatic reactions involving nucleic acid molecules
WO2006095941A1 (en) 2005-03-05 2006-09-14 Seegene, Inc. Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
EP2365079A1 (en) 2005-03-05 2011-09-14 Seegene, Inc. Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
KR20140068234A (en) 2005-03-31 2014-06-05 더 제너럴 하스피탈 코포레이션 Monitoring and modulating hgf/hgfr activity
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
US20060223071A1 (en) * 2005-04-01 2006-10-05 Wisniewski Michele E Methods, compositions, and kits for detecting nucleic acids in a single vessel
EP2360278A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US20060240442A1 (en) * 2005-04-20 2006-10-26 Vevea Dirk N Methods and oligonucleotides for the detection of Salmonella SP., E coli 0157:H7, and Listeria monocytogenes
JP2008539766A (en) 2005-05-17 2008-11-20 オズジーン プロプライアタリー リミテッド Continuous cloning system
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
EP2476761A3 (en) 2005-07-07 2012-10-17 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7892795B2 (en) 2005-08-02 2011-02-22 Focus Diagnostics, Inc. Methods and compositions for detecting BK virus
US7838646B2 (en) 2005-08-18 2010-11-23 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2621267A1 (en) 2005-09-07 2007-03-15 Nugen Technologies, Inc. Improved nucleic acid amplification procedure
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
CA2624324A1 (en) * 2005-10-06 2007-04-19 Lucigen Corporation Thermostable viral polymerases and methods of use
US8609829B2 (en) * 2005-10-17 2013-12-17 Gen-Probe Incorporated Compositions and methods to detect Legionella pneumophila nucleic acid
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
WO2007053358A2 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals, Inc. Methods for identifying compounds of interest using encoded libraries
US7422857B2 (en) 2005-10-28 2008-09-09 University Of South Florida Detection of polyketide synthetase gene expression in Karenia brevis
CN101310183A (en) 2005-11-16 2008-11-19 诺瓦提斯公司 Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
US20070207455A1 (en) * 2005-11-17 2007-09-06 Third Wave Technologies, Inc. Compositions and methods for detecting an HCV-1 subtype
US8313901B2 (en) 2005-12-21 2012-11-20 Yale University Methods and compositions related to the modulation of riboswitches
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
CN101370622B (en) 2006-01-18 2013-07-31 阿戈斯治疗公司 Systems and methods for processing samples in a closed container, and related devices
WO2007087262A2 (en) * 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Selective genome amplification
US20090176878A1 (en) * 2007-10-05 2009-07-09 Washington University In St. Louis Genetic polymorphisms and substance dependence
US20110143344A1 (en) * 2006-03-01 2011-06-16 The Washington University Genetic polymorphisms and substance dependence
US20090061454A1 (en) 2006-03-09 2009-03-05 Brody Jerome S Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
JP5254949B2 (en) 2006-03-15 2013-08-07 マイクロニクス, インコーポレイテッド Integrated nucleic acid assay
US7947441B2 (en) * 2006-04-14 2011-05-24 University Of South Florida Molecular detection and quantification of Enterococci
CA2653248C (en) 2006-05-25 2017-09-26 Monsanto Technology Llc A method to identify disease resistant quantitative trait loci in soybean and compositions thereof
CA2654016C (en) 2006-06-01 2016-01-05 Third Wave Technologies, Inc. Detection of nucleic acids
US11001881B2 (en) 2006-08-24 2021-05-11 California Institute Of Technology Methods for detecting analytes
WO2007149269A2 (en) 2006-06-12 2007-12-27 Oncomethylome Sciences S.A. Methylation markers for early detection and prognosis of colon cancers
WO2008005459A2 (en) * 2006-06-30 2008-01-10 Nugen Technologies, Inc. Methods for fragmentation and labeling of nucleic acids
AU2007273055B2 (en) 2006-07-14 2014-05-01 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
US11525156B2 (en) 2006-07-28 2022-12-13 California Institute Of Technology Multiplex Q-PCR arrays
US8048626B2 (en) 2006-07-28 2011-11-01 California Institute Of Technology Multiplex Q-PCR arrays
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US11560588B2 (en) 2006-08-24 2023-01-24 California Institute Of Technology Multiplex Q-PCR arrays
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
EP2450456A3 (en) 2006-11-02 2012-08-01 Yale University Assessment of oocyte competence
DK2102239T3 (en) 2006-11-30 2012-05-29 Res Dev Foundation IMPROVED IMMUNOGLOBULIN LIBRARIES
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
KR20090100460A (en) * 2007-01-17 2009-09-23 메리디안 바이오사이언스 인크. Stable reagents and kits useful in loop-mediated isothermal amplification(lamp)
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
EA031180B1 (en) 2007-01-29 2018-11-30 Сайнсано Method and device for examining a sample for the presence or absence of two or more independent transformant plant events or material derived therefrom
EP1956097A1 (en) 2007-02-06 2008-08-13 bioMerieux B.V. Method for discriminating single nucleotide polymorphisms (SNPs)
CA2678799A1 (en) * 2007-03-01 2008-09-12 Gen-Probe Incorporated Methods and kits for amplifying dna
US8183359B2 (en) * 2007-03-01 2012-05-22 Gen-Probe Incorporated Kits for amplifying DNA
EP1970440A1 (en) * 2007-03-06 2008-09-17 Qiagen GmbH Polymerase stabilization by ionic detergents
US8445267B2 (en) 2007-04-09 2013-05-21 University Of Florida Research Foundation, Inc. Tyrosine-modified recombinant rAAV vector compositions and methods for use
DK2155789T3 (en) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin Fc libraries
WO2009006438A2 (en) 2007-06-29 2009-01-08 Epicentre Technologies Corporation Copy dna and sense rna
GB0713183D0 (en) * 2007-07-06 2007-08-15 King S College London Method
JP5531367B2 (en) * 2007-08-01 2014-06-25 ダナ−ファーバー キャンサー インスチテュート Target sequence enrichment
EP2185726B1 (en) 2007-08-06 2014-01-08 Orion Genomics, LLC Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
CN101970686B (en) * 2007-09-07 2013-03-27 第三次浪潮技术公司 Methods and applications for target quantification
JP2009077712A (en) 2007-09-11 2009-04-16 F Hoffmann La Roche Ag DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-Raf KINASE INHIBITOR
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
CA2704809A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
EP2071034A1 (en) 2007-12-12 2009-06-17 bioMérieux Method for treating a solution in order to destroy any ribonucleic acid after amplification
ES2686677T3 (en) 2007-12-21 2018-10-19 Biomerieux Sa Methicillin-resistant Staphylococcus aureus detection
US8034568B2 (en) * 2008-02-12 2011-10-11 Nugen Technologies, Inc. Isothermal nucleic acid amplification methods and compositions
EP2250287B1 (en) 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
AU2009225835B2 (en) * 2008-03-15 2013-02-14 Hologic, Inc. Compositions and methods for analysis of nucleic acid molecules during amplification reactions
WO2009117698A2 (en) 2008-03-21 2009-09-24 Nugen Technologies, Inc. Methods of rna amplification in the presence of dna
WO2009115615A2 (en) 2008-03-21 2009-09-24 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
EP2113574A1 (en) 2008-04-28 2009-11-04 Biotype AG Substances and methods for a DNA based profiling assay
JP2009268665A (en) * 2008-05-07 2009-11-19 Canon Inc Inhalation device
US20110177509A1 (en) * 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
GB0814570D0 (en) 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
US20100240024A1 (en) * 2008-09-03 2010-09-23 Abbott Laboratories Assays And Kits For Determining HIV-1 Tropism
CA2679750A1 (en) 2008-09-23 2010-03-23 Nexus Dx, Inc. Methods for detecting nucleic acids in a sample
EP2172563A1 (en) 2008-09-24 2010-04-07 bioMérieux S.A. Method for lowering the dependency towards sequence variation of a nucleic acid target in a diagnostic hybridization assay
ES2637843T3 (en) 2008-10-24 2017-10-17 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US9080211B2 (en) 2008-10-24 2015-07-14 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
ES2805347T3 (en) 2009-02-11 2021-02-11 Caris Mpi Inc Molecular profiling of tumors
ES2544265T3 (en) 2009-02-11 2015-08-28 Orion Genomics, Llc Combinations of polymorphisms to determine the specific expression of IGF2 allele
KR101815716B1 (en) 2009-04-22 2018-01-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma
WO2010124257A2 (en) * 2009-04-24 2010-10-28 Colby Pharmaceutical Company Methods and kits for determining oxygen free radical (ofr) levels in animal and human tissues as a prognostic marker for cancer and other pathophysiologies
WO2010126913A1 (en) 2009-04-27 2010-11-04 Gen-Probe Incorporated Methods and kits for use in the selective amplification of target sequences
SI2427576T1 (en) 2009-05-08 2016-10-28 Seqirus UK Limited Generic assays for detection of influenza viruses
EP2449104B1 (en) 2009-06-29 2014-06-04 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
KR101823872B1 (en) 2009-07-17 2018-01-31 바이오아트라, 엘엘씨 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US8614062B1 (en) 2009-07-24 2013-12-24 University Of South Florida RNA-based system and method to differentiate seafood
US10174368B2 (en) 2009-09-10 2019-01-08 Centrillion Technology Holdings Corporation Methods and systems for sequencing long nucleic acids
US10072287B2 (en) 2009-09-10 2018-09-11 Centrillion Technology Holdings Corporation Methods of targeted sequencing
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
JP5879266B2 (en) 2009-09-14 2016-03-08 シラジェン バイオセラピューティクス インコーポレイテッド Combined cancer therapy with oncolytic vaccinia virus
WO2011036173A1 (en) 2009-09-24 2011-03-31 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
AU2010315400B2 (en) 2009-10-27 2016-07-21 Caris Mpi, Inc. Molecular profiling for personalized medicine
EP3461889A1 (en) 2009-11-19 2019-04-03 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
WO2011066476A1 (en) * 2009-11-25 2011-06-03 Quantalife, Inc. Methods and compositions for detecting genetic material
WO2011071923A2 (en) 2009-12-07 2011-06-16 Illumina, Inc. Multi-sample indexing for multiplex genotyping
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
BR112012013664B1 (en) 2009-12-10 2020-11-10 Turnstone Limited Partnership oncolitic rhabdovirus
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2011084772A2 (en) 2009-12-21 2011-07-14 Northwestern University Allelic disorders caused by mutations in trpv4
US20110151457A1 (en) 2009-12-22 2011-06-23 Elitech Holding B.V. Hypertheromostable endonuclease iv substrate probe
CA2822747A1 (en) 2009-12-23 2011-06-30 Arca Biopharma, Inc. Use of s-(6-nitro-oxi-hexahydro-furo[3,2-b]thioacetate in the treatment of cardiovascular disorders associated with oxide synthase dysfunction
WO2011082325A2 (en) 2009-12-31 2011-07-07 Life Technologies Corporation Sequences of e.coli 055:h7 genome
CA2786569C (en) 2010-01-29 2019-04-09 Micronics, Inc. Sample-to-answer microfluidic cartridge
EP2545189B1 (en) 2010-03-08 2018-01-10 Dana-Farber Cancer Institute, Inc. Full cold-pcr enrichment with reference blocking sequence
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CA2832672A1 (en) 2010-04-16 2011-10-20 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
CN103079567A (en) 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
DK2561067T3 (en) 2010-04-23 2019-03-11 Univ Florida RAAV-GUANYLAT CYCLE COMPOSITIONS AND PROCEDURES FOR TREATING LEVERS CONGENITAL AMAUROSE-1 (LCA1)
EP3508854A1 (en) 2010-04-27 2019-07-10 The Regents of The University of California Cancer biomarkers and methods of use thereof
JP5454338B2 (en) 2010-04-28 2014-03-26 株式会社島津製作所 Real-time nucleic acid amplification by droplet manipulation
US10232374B2 (en) 2010-05-05 2019-03-19 Miroculus Inc. Method of processing dried samples using digital microfluidic device
KR101176139B1 (en) 2010-05-20 2012-08-22 광주과학기술원 Transgenic Mice Overexpressing HIF-2α as an Animal Model of Arthritis and Uses Thereof
KR101223660B1 (en) 2010-05-20 2013-01-17 광주과학기술원 Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient
ES2647612T3 (en) 2010-06-04 2017-12-22 Chronix Biomedical Biomarkers of circulating nucleic acids associated with prostate cancer
WO2012009711A2 (en) 2010-07-16 2012-01-19 Tocagen Inc. Retrovirus detection
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
JP5933544B2 (en) 2010-07-26 2016-06-08 バイオマトリカ, インコーポレーテッド Compositions for stabilizing blood DNA, RNA and proteins and other biological samples shipped and stored at ambient temperature
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
EP2614163B1 (en) 2010-09-07 2016-01-06 Novartis AG Generic assays for detection of mammalian reovirus
WO2012040619A2 (en) 2010-09-24 2012-03-29 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
NZ608972A (en) 2010-10-01 2015-09-25 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof
US10233501B2 (en) 2010-10-19 2019-03-19 Northwestern University Biomarkers predictive of predisposition to depression and response to treatment
US10093981B2 (en) 2010-10-19 2018-10-09 Northwestern University Compositions and methods for identifying depressive disorders
US20150225792A1 (en) 2014-01-17 2015-08-13 Northwestern University Compositions and methods for identifying depressive disorders
US20150218639A1 (en) 2014-01-17 2015-08-06 Northwestern University Biomarkers predictive of predisposition to depression and response to treatment
CN105772122B (en) 2010-12-21 2017-11-03 株式会社岛津制作所 Apparatus and method for for the operation object composition in pipe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
CA2824277C (en) 2011-01-04 2021-08-31 Jennerex, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US20120190020A1 (en) 2011-01-25 2012-07-26 Aria Diagnostics, Inc. Detection of genetic abnormalities
US9637792B2 (en) 2011-02-02 2017-05-02 Mayo Foundation For Medical Education And Research Digital sequence analysis of DNA methylation
WO2012109133A1 (en) 2011-02-07 2012-08-16 Research Development Foundation Engineered immunoglobulin fc polypeptides
EP3940084A1 (en) 2011-02-09 2022-01-19 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
WO2012115648A1 (en) 2011-02-24 2012-08-30 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a feline
KR20140006963A (en) 2011-02-25 2014-01-16 노파르티스 아게 Exogenous internal positive control
WO2012158238A2 (en) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender
WO2012118745A1 (en) 2011-02-28 2012-09-07 Arnold Oliphant Assay systems for detection of aneuploidy and sex determination
WO2012120377A2 (en) 2011-03-08 2012-09-13 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
ES2656557T3 (en) 2011-03-31 2018-02-27 Dana-Farber Cancer Institute, Inc. Method to enrich single-stranded mutant sequences from a mixture of natural and mutant sequences
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120252682A1 (en) 2011-04-01 2012-10-04 Maples Corporate Services Limited Methods and systems for sequencing nucleic acids
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
KR101291668B1 (en) 2011-04-21 2013-08-01 서울대학교산학협력단 Shuttle Vectors for Mycobacteria-Escherichia coli and Uses Thereof
KR102007444B1 (en) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 Truncated hiv envelope proteins(env), methods and compositions related thereto
US8993341B2 (en) 2011-05-12 2015-03-31 Exact Sciences Corporation Removal of PCR inhibitors
CN107312774A (en) 2011-05-12 2017-11-03 精密科学公司 The separation of nucleic acid
US8808990B2 (en) 2011-05-12 2014-08-19 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
CA2872045A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
JP5930556B2 (en) 2011-06-15 2016-06-08 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Compositions and methods for diagnosing and monitoring hyperthyroidism in felines
US20120322676A1 (en) 2011-06-17 2012-12-20 Life Technologies Corporation Compositions and methods for detection of cronobacter spp. and cronobacter species and strains
EP3564393A1 (en) 2011-06-21 2019-11-06 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
WO2013024173A1 (en) 2011-08-17 2013-02-21 Technische Universität München Computer implemented method for identifying regulatory regions or regulatory variations
DK2748332T3 (en) 2011-08-24 2018-07-16 Oxoid Ltd COMPOSITIONS AND METHODS FOR DETECTING MULTIPLE MICROORGANISMS
MX2014002307A (en) 2011-08-31 2014-08-26 Hoffmann La Roche Method for predicting risk of hypertension associated with anti-angiogenesis therapy.
AU2012300985A1 (en) 2011-08-31 2014-02-13 F. Hoffmann-La Roche Ag Responsiveness to angiogenesis inhibitors
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
DE19216461T1 (en) 2011-10-03 2021-10-07 Modernatx, Inc. MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USES THEREOF
FR2981088B1 (en) 2011-10-06 2013-11-29 Biomerieux Sa RNA POLYMERASES MUTEES
CN104080958A (en) 2011-10-19 2014-10-01 纽亘技术公司 Compositions and methods for directional nucleic acid amplification and sequencing
US20140303008A1 (en) 2011-10-21 2014-10-09 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
BR112014011491A2 (en) 2011-11-14 2017-05-09 Nestec Sa trials and methods for selecting a treatment regimen for an individual with depression
WO2013076029A1 (en) 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Responsiveness to angiogenesis inhibitors
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013095935A1 (en) 2011-12-19 2013-06-27 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US20140349858A1 (en) 2011-12-22 2014-11-27 Ibis Bioscience, Inc. Amplification of a sequence from a ribonucleic acid
JP5807542B2 (en) 2011-12-22 2015-11-10 株式会社島津製作所 Chip device for manipulating target components and method using the same
US9115394B2 (en) 2011-12-22 2015-08-25 Roche Molecular Systems, Inc. Methods and reagents for reducing non-specific amplification
US9394573B2 (en) 2011-12-23 2016-07-19 Biomerieux S.A. Detection of mecA variant strains of methicillin-resistant Staphylococcus aureus
EP2798089B1 (en) 2011-12-30 2018-05-23 Bio-rad Laboratories, Inc. Methods and compositions for performing nucleic acid amplification reactions
GB2513793B (en) 2012-01-26 2016-11-02 Nugen Tech Inc Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
WO2013116698A2 (en) 2012-02-02 2013-08-08 Invenra, Inc. High throughput screen for biologically active polypeptides
EP2827882B1 (en) 2012-02-21 2020-04-08 Cytonics Corporation Systems, compositions, and methods for transplantation
EP2820174B1 (en) 2012-02-27 2019-12-25 The University of North Carolina at Chapel Hill Methods and uses for molecular tags
EP3321378B1 (en) 2012-02-27 2021-11-10 Becton, Dickinson and Company Compositions for molecular counting
MX2014011682A (en) 2012-03-29 2015-01-22 Novartis Ag Pharmaceutical diagnostic.
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP2834369B1 (en) 2012-04-02 2018-05-30 Life Technologies Corporation Compositions and methods for detection of mycobacterium avium paratuberculosis
CN116064734A (en) 2012-04-19 2023-05-05 生命技术公司 Nucleic acid amplification
EP3461910B1 (en) 2012-04-19 2020-08-26 Life Technologies Corporation Nucleic acid amplification
US9133490B2 (en) 2012-05-16 2015-09-15 Transgenomic, Inc. Step-up method for COLD-PCR enrichment
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
WO2013177220A1 (en) 2012-05-21 2013-11-28 The Scripps Research Institute Methods of sample preparation
AU2013205064B2 (en) 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
EP2861787B1 (en) 2012-06-18 2017-09-20 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US20140005061A1 (en) 2012-06-29 2014-01-02 Life Technologies Corporation Compositions and methods for detection of multiple microorganisms
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
EP2875156A4 (en) 2012-07-19 2016-02-24 Ariosa Diagnostics Inc Multiplexed sequential ligation-based detection of genetic variants
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
EP2895620B1 (en) 2012-09-11 2017-08-02 Life Technologies Corporation Nucleic acid amplification
WO2014043143A1 (en) 2012-09-11 2014-03-20 Life Technologies Corporation Nucleic acid amplification
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
ES2921623T3 (en) 2012-11-26 2022-08-30 Modernatx Inc terminally modified RNA
ES2730690T3 (en) 2012-12-07 2019-11-12 Suppremol Gmbh Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
CN104919191B (en) 2012-12-21 2019-07-09 精密公司 Fluid circuit and relevant manufacturing method
US20150346097A1 (en) 2012-12-21 2015-12-03 Micronics, Inc. Portable fluorescence detection system and microassay cartridge
WO2014100743A2 (en) 2012-12-21 2014-06-26 Micronics, Inc. Low elasticity films for microfluidic use
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
MX2015010783A (en) 2013-02-21 2016-06-21 Children S Hospital Of Eastern Ontario Res Inst Inc Vaccine composition.
US9994911B2 (en) 2013-03-14 2018-06-12 Mayo Foundation For Medical Education And Research Detecting neoplasm
AU2013202805B2 (en) 2013-03-14 2015-07-16 Gen-Probe Incorporated System and method for extending the capabilities of a diagnostic analyzer
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9255265B2 (en) 2013-03-15 2016-02-09 Illumina, Inc. Methods for producing stranded cDNA libraries
KR101403507B1 (en) 2013-03-21 2014-06-09 주식회사 현일바이오 Methods for Selectively Detecting Mycobacterium tuberculosis complex and Nontuberculous mycobacteria and Kits Using the Same
KR101507505B1 (en) 2013-04-18 2015-04-07 사회복지법인 삼성생명공익재단 A Method for Diagnosing Myotonic Dystrophy Type 1
US10386377B2 (en) 2013-05-07 2019-08-20 Micronics, Inc. Microfluidic devices and methods for performing serum separation and blood cross-matching
CA2911303C (en) 2013-05-07 2021-02-16 Micronics, Inc. Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions
EP2994543B1 (en) 2013-05-07 2018-08-15 Micronics, Inc. Device for preparation and analysis of nucleic acids
GB201308313D0 (en) 2013-05-09 2013-06-19 Medical Res Council Assay Method
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
LT3004388T (en) 2013-05-29 2019-01-25 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
CN105074011B (en) 2013-06-13 2020-10-02 阿瑞奥萨诊断公司 Statistical analysis for non-invasive chromosomal aneuploidy determination
SG11201600550WA (en) 2013-07-25 2016-02-26 Dch Molecular Diagnostics Inc Methods and compositions for detecting bacterial contamination
US9547006B2 (en) 2013-08-08 2017-01-17 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
KR102536833B1 (en) 2013-08-28 2023-05-26 벡톤 디킨슨 앤드 컴퍼니 Massively parallel single cell analysis
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
CA2924669C (en) 2013-09-20 2023-03-21 The Regents Of The University Of Michigan Compositions and methods for the analysis of radiosensitivity
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
US20150098940A1 (en) 2013-10-03 2015-04-09 Oklahoma Medical Research Foundation Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare
US10253358B2 (en) 2013-11-04 2019-04-09 Exact Sciences Development Company, Llc Multiple-control calibrators for DNA quantitation
CA2929596C (en) 2013-11-13 2022-07-05 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
US9909181B2 (en) 2013-12-13 2018-03-06 Northwestern University Biomarkers for post-traumatic stress states
WO2015095689A1 (en) 2013-12-19 2015-06-25 Exact Sciences Corporation Synthetic nucleic acid control molecules
EP3447493B1 (en) 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
US9663770B2 (en) 2014-01-22 2017-05-30 Life Technologies Corporation Reverse transcriptases for use in high temperature nucleic acid synthesis
WO2015113725A1 (en) 2014-02-03 2015-08-06 Thermo Fisher Scientific Baltics Uab Method for controlled dna fragmentation
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
EP3572093A1 (en) 2014-03-31 2019-11-27 Debiopharm International SA Fgfr fusions
WO2015153284A1 (en) 2014-03-31 2015-10-08 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
ES2786373T3 (en) 2014-06-10 2020-10-09 Biomatrica Inc Platelet stabilization at room temperatures
KR20170016915A (en) 2014-06-11 2017-02-14 마이크로닉스 인코포레이티드. Microfluidic cartridges and apparatus with integrated assay controls for analysis of nucleic acids
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CN106661600B (en) 2014-07-16 2021-04-06 唐恩生物科技股份有限公司 Isothermal method for amplifying nucleic acid samples
CN107075581B (en) 2014-08-06 2022-03-18 纽亘技术公司 Digital measurement by targeted sequencing
CA2960821A1 (en) 2014-09-09 2016-03-17 Igenomx International Genomics Corporation Methods and compositions for rapid nucleic acid library preparation
US11559801B2 (en) 2014-11-03 2023-01-24 Tangen Biosciences, Inc. Apparatus and method for cell, spore, or virus capture and disruption
JP7231326B2 (en) 2014-11-10 2023-03-01 ジェネンテック, インコーポレイテッド Therapeutic and diagnostic methods for IL-33-mediated disorders
EP3224362A4 (en) 2014-11-26 2018-06-06 The Regents of The University of California Therapeutic compositions comprising transcription factors and methods of making and using the same
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
JP6759229B2 (en) 2014-12-08 2020-09-23 バーグ エルエルシー Use of markers containing filamin A in the diagnosis and treatment of prostate cancer
ES2879964T3 (en) 2014-12-12 2021-11-23 Exact Sciences Dev Co Llc Compositions and Methods for Performing Methylation Detection Assays
EP3230476B1 (en) 2014-12-12 2020-02-05 Exact Sciences Development Company, LLC Zdhhc1 for normalizing methylation detection assays
KR101718800B1 (en) 2015-01-21 2017-03-24 주식회사 디알나노 Nanocomplexs for Co-delivering a Drug and siRNA and Uses Thereof
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
US9708647B2 (en) 2015-03-23 2017-07-18 Insilixa, Inc. Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays
CN107532124B (en) 2015-03-27 2022-08-09 精密科学公司 Detection of esophageal disorders
CN107849603B (en) 2015-04-24 2022-01-28 阿提拉生物系统公司 Amplification of primers with limited nucleotide composition
WO2016174130A1 (en) 2015-04-28 2016-11-03 Université De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
CN108026494A (en) 2015-06-05 2018-05-11 米罗库鲁斯公司 Limitation evaporation and the digital microcurrent-controlled apparatus and method of air matrix of surface scale
CN208562324U (en) 2015-06-05 2019-03-01 米罗库鲁斯公司 Digital microcurrent-controlled (DMF) device of air matrix
JP6698708B2 (en) 2015-06-09 2020-05-27 ライフ テクノロジーズ コーポレーション Methods, systems, compositions, kits, devices, and computer-readable media for molecular tagging
US10894980B2 (en) 2015-07-17 2021-01-19 President And Fellows Of Harvard College Methods of amplifying nucleic acid sequences mediated by transposase/transposon DNA complexes
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
JP6630742B2 (en) 2015-08-17 2020-01-15 クラ オンコロジー, インコーポレイテッド Method of treating a cancer patient with a farnesyltransferase inhibitor
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US9499861B1 (en) 2015-09-10 2016-11-22 Insilixa, Inc. Methods and systems for multiplex quantitative nucleic acid amplification
EP3362580B1 (en) 2015-10-18 2021-02-17 Affymetrix, Inc. Multiallelic genotyping of single nucleotide polymorphisms and indels
KR101651817B1 (en) 2015-10-28 2016-08-29 대한민국 Primer set for Preparation of NGS library and Method and Kit for making NGS library using the same
KR20180068985A (en) 2015-10-30 2018-06-22 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 Detection of complex amplification and separation and detection of DNA from plasma
EP3387411B1 (en) 2015-12-08 2023-05-10 Biomatrica, INC. Reduction of erythrocyte sedimentation rate
EP3387147A1 (en) 2015-12-09 2018-10-17 Life Technologies Corporation Detection and quantification of nucleic acid molecules associated with a surface
WO2017121836A1 (en) 2016-01-15 2017-07-20 Thermo Fisher Scientific Baltics Uab Thermophilic dna polymerase mutants
KR101845957B1 (en) 2016-02-23 2018-04-05 전남대학교기술지주회사(주) Kit for diagnosis of leukemia and diagnostic method targeting prohibitin gene
WO2017155858A1 (en) 2016-03-07 2017-09-14 Insilixa, Inc. Nucleic acid sequence identification using solid-phase cyclic single base extension
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
CN116064796A (en) 2016-05-05 2023-05-05 精密科学公司 Detection of lung tumors by analysis of methylated DNA
US20170321286A1 (en) 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
CA3029838A1 (en) 2016-07-19 2018-01-25 Exact Sciences Development Company, Llc Nucleic acid control molecules from non-human organisms
EP3978624A1 (en) 2016-07-19 2022-04-06 Exact Sciences Corporation Methylated control dna
CA3033016A1 (en) 2016-08-10 2018-02-15 Institut Pasteur Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria
CN109715781A (en) 2016-08-22 2019-05-03 米罗库鲁斯公司 Feedback system for the parallel drop control in digital microcurrent-controlled equipment
CN109790198B (en) 2016-09-02 2022-09-09 梅约医学教育与研究基金会 Detection of hepatocellular carcinoma
WO2018071522A1 (en) 2016-10-11 2018-04-19 Life Technologies Corporation Rapid amplification of nucleic acids
HUE053927T2 (en) 2016-11-03 2021-07-28 Kura Oncology Inc Farnesyltransferase inhibitors for use in treating cancer
US11371090B2 (en) 2016-12-12 2022-06-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection
WO2018126082A1 (en) 2016-12-28 2018-07-05 Miroculis Inc. Digital microfluidic devices and methods
EP4095263A1 (en) 2017-01-06 2022-11-30 Editas Medicine, Inc. Methods of assessing nuclease cleavage
KR101936799B1 (en) 2017-01-09 2019-01-11 주식회사 엠이티라이프사이언스 Pharmaceutical Composition for Treating Oral Precancer and Method for Predicting or Detecting of Oral Precancer or Oral Cancer
CN110462062A (en) 2017-01-26 2019-11-15 俄克拉荷马医学研究基金会 Systemic loupus erythematosus Disease Activity, intensity and the biomarker of acute attack
AU2018211956A1 (en) 2017-01-27 2019-07-25 Exact Sciences Corporation Detection of colon neoplasia by analysis of methylated DNA
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018156609A1 (en) 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3057325C (en) 2017-03-24 2024-03-12 Gen-Probe Incorporated Cover assembly and related methods of use
US11623219B2 (en) 2017-04-04 2023-04-11 Miroculus Inc. Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets
US10914729B2 (en) 2017-05-22 2021-02-09 The Trustees Of Princeton University Methods for detecting protein binding sequences and tagging nucleic acids
US10995104B2 (en) 2017-05-30 2021-05-04 Roche Molecular System, Inc. Catalysts for reversing formaldehyde adducts and crosslinks
EP3631008A1 (en) 2017-06-02 2020-04-08 Affymetrix, Inc. Array-based methods for analysing mixed samples using differently labelled allele-specific probes
WO2018223053A1 (en) 2017-06-02 2018-12-06 Affymetrix, Inc. Array-based methods for analysing mixed samples using differently labelled allele-specific probes
GB2578038B (en) 2017-06-16 2022-11-23 Life Technologies Corp Control nucleic acids, and compositions, kits, and uses thereof
US11618891B2 (en) 2017-06-26 2023-04-04 Thermo Fisher Scientific Baltics Uab Thermophilic DNA polymerase mutants
CN111032209A (en) 2017-07-10 2020-04-17 简·探针公司 Analysis system and method
WO2019017680A2 (en) 2017-07-19 2019-01-24 국민대학교 산학협력단 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME
KR101956315B1 (en) 2017-07-19 2019-03-08 국민대학교 산학협력단 miR494 as a biomarker for parkinson’s disease and diagnostic kit using thereof
US11174511B2 (en) 2017-07-24 2021-11-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture
CN110892258A (en) 2017-07-24 2020-03-17 米罗库鲁斯公司 Digital microfluidic system and method with integrated plasma collection device
WO2019032489A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN115582155A (en) 2017-09-01 2023-01-10 米罗库鲁斯公司 Digital microfluidic device and method of use thereof
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019094578A1 (en) 2017-11-09 2019-05-16 Alnylam Pharmaceuticals Inc. Assays and methods for determining expression of the lect2 gene
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
WO2019130347A1 (en) 2017-12-26 2019-07-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Primers for isothermal amplification of mpt64 gene of mycobacterium tuberculosis and the process thereof
CA3089078A1 (en) 2018-01-29 2019-08-01 Gen-Probe Incorporated Analytical systems and methods
KR20220098056A (en) 2018-02-09 2022-07-08 제넨테크, 인크. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
EP3775272A4 (en) 2018-04-02 2021-12-29 Progenity, Inc. Methods, systems, and compositions for counting nucleic acid molecules
EP3691635B1 (en) 2018-05-25 2023-07-05 Arca Biopharma, Inc. Methods and compositions involving bucindolol for the treatment of atrial fibrillation
WO2020014400A1 (en) 2018-07-10 2020-01-16 Gen-Probe Incorporated Methods and systems for detecting and quantifying nucleic acids
US11408030B2 (en) 2018-09-10 2022-08-09 Andy Madrid Test for detecting Alzheimer's disease
AU2019339508A1 (en) 2018-09-14 2021-04-15 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
CA3117112A1 (en) 2018-10-31 2020-05-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers and methods of use for radiation-induced lung injury
JP2022506463A (en) 2018-11-01 2022-01-17 クラ オンコロジー, インコーポレイテッド How to Treat Cancer with Farnesyltransferase Inhibitors
CA3117768A1 (en) 2018-11-28 2020-06-04 Keygene N.V. Targeted enrichment by endonuclease protection
MX2021006234A (en) 2018-11-30 2021-09-10 Caris Mpi Inc Next-generation molecular profiling.
WO2020142347A2 (en) 2018-12-31 2020-07-09 Gen-Probe Incorporated Systems and methods for filling multi-well cartridges with solid reagents
CN113474466A (en) 2019-02-21 2021-10-01 主基因有限公司 Polyploid genotyping
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3937780A4 (en) 2019-03-14 2022-12-07 InSilixa, Inc. Methods and systems for time-gated fluorescent-based detection
CA3134825A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3947718A4 (en) 2019-04-02 2022-12-21 Enumera Molecular, Inc. Methods, systems, and compositions for counting nucleic acid molecules
EP3953041A4 (en) 2019-04-08 2023-01-25 Miroculus Inc. Multi-cartridge digital microfluidics apparatuses and methods of use
EP3956476A1 (en) 2019-04-17 2022-02-23 Igenomix S.L. Improved methods for the early diagnosis of uterine leiomyomas and leiomyosarcomas
KR20220015394A (en) 2019-04-30 2022-02-08 라리마 테라퓨틱스, 인코포레이티드 Frataxin sensitivity markers for determining the efficacy of prataxin replacement therapy
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3137749C (en) 2019-05-03 2023-12-05 Gen-Probe Incorporated Receptacle transport system for an analytical system
US11524298B2 (en) 2019-07-25 2022-12-13 Miroculus Inc. Digital microfluidics devices and methods of use thereof
AU2020374985A1 (en) 2019-10-31 2022-05-26 Exact Sciences Corporation Detecting ovarian cancer
IL293489A (en) 2019-12-02 2022-08-01 Caris Mpi Inc Pan-cancer platinum response predictor
JP2023505712A (en) 2019-12-12 2023-02-10 キージーン ナムローゼ フェンノートシャップ Nucleic acid manipulation in semi-solid state
WO2021123062A1 (en) 2019-12-20 2021-06-24 Keygene N.V. Ngs library preparation using covalently closed nucleic acid molecule ends
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
CN113736858A (en) 2020-05-28 2021-12-03 香港科技大学 Real-time monitoring method of nucleic acid amplicon mediated by circular oligonucleotide probe
WO2021246820A1 (en) 2020-06-05 2021-12-09 주식회사 씨젠 Specimen transport kit for detecting respiratory pathogens and methods for detecting respiratory pathogens using same
EP4200445A1 (en) 2020-08-19 2023-06-28 Mayo Foundation for Medical Education and Research Detecting non-hodgkin lymphoma
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
AU2021345359A1 (en) 2020-09-21 2023-05-11 Progenity, Inc. Compositions and methods for isolation of cell-free dna
EP4225914A1 (en) 2020-10-06 2023-08-16 Keygene N.V. Targeted sequence addition
CN116323440A (en) 2020-10-21 2023-06-23 简·探针公司 Fluid container management system
US20240002904A1 (en) 2020-11-24 2024-01-04 Keygene N.V. Targeted enrichment using nanopore selective sequencing
EP4251750A1 (en) 2020-11-25 2023-10-04 Koninklijke Nederlandse Akademie van Wetenschappen Ribosomal profiling in single cells
WO2022216841A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
WO2022216846A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
CA3214833A1 (en) 2021-04-06 2022-10-13 Bpgbio, Inc. Protein markers for the prognosis of breast cancer progression
WO2022265965A1 (en) 2021-06-14 2022-12-22 10X Genomics, Inc. Reverse transcriptase variants for improved performance
EP4314286A1 (en) 2021-08-06 2024-02-07 Sansure Biotech Inc. Compositions for liquefying a viscous biological sample, combination products, liquefying agents, and kits thereof, and methods and application thereof
US11772093B2 (en) 2022-01-12 2023-10-03 Miroculus Inc. Methods of mechanical microfluidic manipulation
WO2023196937A1 (en) 2022-04-06 2023-10-12 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
US20240010742A1 (en) 2022-06-10 2024-01-11 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024015331A1 (en) 2022-07-12 2024-01-18 Genentech, Inc. Therapeutic and diagnostic methods for multiple sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK171161B1 (en) * 1985-03-28 1996-07-08 Hoffmann La Roche A method for detecting the presence or absence of at least one specific nucleic acid sequence in a sample or for distinguishing two different nucleic acid sequences in this sample
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
JP2517241B2 (en) * 1986-08-19 1996-07-24 郁男 山科 gene
EP0272098A3 (en) * 1986-12-15 1990-06-06 City Of Hope National Medical Center Method for amplification and detection of rna sequences
IL86724A (en) * 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
IE72468B1 (en) * 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
DE3726934A1 (en) * 1987-08-13 1989-02-23 Merck Patent Gmbh METHOD FOR DETECTING NUCLEIC ACID SEQUENCES
DE68908054T2 (en) * 1988-01-21 1994-03-10 Genentech Inc REINFORCEMENT AND DETECTION OF NUCLEIC ACID SEQUENCES.
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
JP3152927B2 (en) * 1988-12-16 2001-04-03 アクゾ・ノベル・ナムローゼ・フェンノートシャップ Self-sustaining, sequence replication system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044184B2 (en) 2004-04-26 2011-10-25 Wako Pure Chemical Industries, Ltd. Probe and primer for tubercle bacillus detection, and method of detecting human tubercle bacillus therewith
US8628926B2 (en) 2004-04-26 2014-01-14 Wako Pure Chemical Industries, Ltd. Probe and primer for tubercle bacillus detection, and method of detecting human tubercle bacillus therewith

Also Published As

Publication number Publication date
US5409818A (en) 1995-04-25
DE3850093D1 (en) 1994-07-14
KR890013184A (en) 1989-09-21
EP0329822A3 (en) 1990-08-01
ATE106948T1 (en) 1994-06-15
WO1991002814A1 (en) 1991-03-07
ES2053648T3 (en) 1994-08-01
EP0329822B1 (en) 1994-06-08
KR960015744B1 (en) 1996-11-20
KR920702866A (en) 1992-10-28
EP0329822A2 (en) 1989-08-30
DE3850093T2 (en) 1994-11-03

Similar Documents

Publication Publication Date Title
CA1340807C (en) Nucleic acid amplification process
US5554517A (en) Nucleic acid amplification process
US5130238A (en) Enhanced nucleic acid amplification process
US5618703A (en) Unconventional nucleotide substitution in temperature selective RT-PCR
EP0506889B1 (en) High temperature reverse transcriptases
US5466586A (en) Method for the synthesis of ribonucleic acid (RNA)
AU711589B2 (en) Terminal repeat amplification method
KR100242252B1 (en) Nucleic acid sequence amplification methods
US5322770A (en) Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US6063604A (en) Target nucleic acid sequence amplification
JPH05292968A (en) Improvement for nucleic acid amplification
JPH02503054A (en) Nucleic acid sequence amplification and detection
WO1990001068A1 (en) Sequence specific assay for the detection of a nucleic acid molecule
IE892698A1 (en) Nucleic acid amplification process

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20161102